CLINICAL STUDY PROTOCOL  
A PHASE 4, MULTICENTER STUDY TO EVALUATE 
DISCONTINUATION AND RE -TREATMENT IN 
SUBJECTS WITH TENOSYNOVIAL GIANT CELL 
TUMOR (TGCT)  PREVIOUSLY TREATED WITH 
PEXIDARTINIB  
 
PEXIDARTINIB TGCT CONTINUATION STUDY  
 
PROTOCOL NUMBER:   PL3397 -A-U4003  
IND NUMBER :  117,332  
NCT NUMBER:  [STUDY_ID_REMOVED]  
[EudraCT NUMBER :  2020 -000192 -20] 
 
VERSION  2.0, 25 Feb 2022  
 
DAIICHI SANKYO , INC. 
211 Mt. Airy Road  
Basking Ridge, NJ 07920 United States  
 
CONFIDENTIALITY STATEMENT  
Information contained in this document is proprietary to Daiichi Sankyo, Inc.   The information is 
provided to you in confidence which is requested under an agreed upon and signed 
Confidential ity and Disclosure Agreement.  Do not give this document or any copy of it or reveal 
any proprietary information contained in it to any third party (other than those in your 
organization who are assisting you in this work and are bound by the Confidentiali ty and 
Disclosure Agreement) without the prior written permission of an authorized representative of 
Daiichi Sankyo Inc.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 2 INVESTIGATOR  AGREEMENT  
A Phase 4, multicenter study to evaluate the discontinuation and 
re-treatment in subjects with tenosynovial giant cell tumor (TGC T) 
previously treated with pexidartinib  
Investigator ’s Signature:  
I have fully discussed the objectives of this study and the contents of this protocol with the 
Sponsor’s representative.  
I understand that information contained in or pertaining to this protocol is confidential and 
should not be disclosed, other than to those directly involved in the execution or the ethical 
review of the study, without written authorization from the Sponsor.  It is, however, 
permissible to provide information to a subject in order to obtain consent.  
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to c onduct the study in 
accordance with International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (ICH E6[R2]), 
which has its foundations in the Declaration of Helsinki, and a pplicable regional regulatory 
requirements.  
I agree to make available to Sponsor personnel, their representatives and relevant regulatory 
authorities, my subjects’ study records in order to verify the data that I have entered into the 
case report forms.  I  am aware of my responsibilities as a Principal Investigator  as provided 
by the Sponsor.  
I understand that the Sponsor may decide to suspend or prematurely terminate the study at 
any time for whatever reason; such a decision will be communicated to me in w riting.  
Conversely, should I decide to withdraw from execution of the study, I will communicate my 
intention immediately in writing to the Sponsor.  
     
 Print Name   Signature   
     
 Title   Date (DD MMM YYYY)   
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 3 DOCUMENT HISTORY  
Version Number  Version Date  
2.0 25 Feb  2022  
1.0 21 Feb 2020  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 4 SUMMARY OF CHANGES  
Please refer to the comparison document for protocol V2.0 (dated 25 Feb  2022 ) versus protocol 
V1.0 (dated 21 Feb 2020) for actual changes in text.  The summary of changes below is a topline 
summary of major changes in the current PL3397 -A-U4003 clinical study protocol (V2.0) by 
section.  
Amendment Rationale:  
This amendment is for  clarificat ion update s to the scheduled visits and required assessments for 
operational and clinical safety purposes.  Additionally, language has been added for the 
collection of COVID -19-related data.  
CONVENTIONS USED IN THIS SUMMARY OF CHANGES  
All locations (Secti on numbers and/or paragraph/bullet numbers) refer to the current protocol 
version, which incorporates the items specified in this Summary of Changes document.  
Minor edits, such as update to language that does not alter original meaning, update to version 
numbering, formatting, change in font color, corrections to typographical errors, use of 
abbreviations, moving verbiage within a section or table, change in style, or change in case, 
are not noted in the table below.  
Section # and Title  Description of Change  Brief Rationale  
 Cover page  
 1.1 Protocol Synopsis  Added NCT number  NCT number was received  
 Investigator Agreement  Removed Sponsor signature  section  Veeva Vault electronic 
signature page to replace 
sponsor wet -ink signature  
 1.1 Protocol Synopsis  
 5.1 Inclusion Criteria  Updated contraception language for 
donating sperm/ova during study 
treatment  Updated language for 
additional clarity  
 Table 1.1 Schedule of Events:  
Treatment Continuation Cohort  
 Table 1.2 Schedule of Events:  
Treatment -Free Period of 
Treatment -Free/Re -Treatment 
Cohort  
 Table 1.3 Schedule of Events:  
Re-Treatment Period of 
Treatment -Free/Re -Treatment 
Cohort  Updated all 3 Schedule of Events tables 
to: 
 Add clarifying language for ECG  
timing (moved from vitals 
assessments) and frequency (also 
in Section 8.4.5 Other Safety)  
 Separate out TSH from hormone 
testing  (also in Section 8.4.3 
Clinical Laboratory Evaluations 
and Table 10.1 Clinical Laborat ory 
Tests)  
 Update visits when dosing diar y is 
provided to patients  
 Add a row for collection of End of 
Study form  
 Defined a month as a 28 -day 
interval for the M1/M2 visit for 
retreatment patients in the 
Treatment -Free/Re -Treatment Updated t o more accurately 
reflect the visit schedules and 
the required assessments  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 5 CONVENTIONS USED IN THIS SUMMARY OF CHANGES  
Cohort and as a 30 -day interval for 
all other cohorts/visits  
 
(Table 1.1 and 1.3 only)  
 Clarified that MRI scans are 
required every 6 months for 
subjects in the Treatment 
Continuation Cohort and every 3 
months for those in the Treatment -
free period and Re -Treatment 
periods of the Treatment -Free/Re -
Treatment Cohort (al so in Sections 
1 Protocol Summary and 4.1.1 
Design Overview)  
 Clarified that subjects from 
Treatment Free/Re -Treatment 
Cohort restarting treatment should 
note MRI as due to progression 
and use the BL2 assessment as 
reference (also in Section 4.1.1 
Design Ov erview)  
 Clarified that urinalysis 
assessments will be performed at 
6-month intervals (also in Section 
1 Protocol Summary)  
 Separated EOT and EOS/AE 
Follow -up as 2  separate visits  and 
reinforced that EOT must occur 
within 24 months after enrollment  
 Removed e ntry for on -site study 
drug administration (also in 
Section 6.2.2 Administration)  
 
(Table 1.2 only)  
 Updated visits to:  
o make  M12 its own visit  
o combine M24 and EOT  
o make  EOS/AE Follow -up its 
own visit  
 Removed comments language for 
AE and ConMed rows  
 4.1.1 Design Overview  
 Table 10.1 Clinical Laboratory 
Tests  Added coagulation, ECG, and hormone 
testing to list of ongoing safety 
monitoring  and made  albumin globulin 
(A/G) ratio  optional  Completeness of list  
 4.1.3 Dose Regimen  
 6.1 Study Drug(s) Description  Reinforced message that dose 
escalations are not permitted  Reinforcing existing language  
 Section 4.1.4 Duration  Clarified frequency of study 
assessments for the Re -Treatment 
period of the Treatment -Free/Re -
Treatment Cohort  Updated language for 
additional clarity  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 6 CONVENTIONS USED IN THIS SUMMARY OF CHANGES  
 6.6 Prior and Concomitant 
Medications  
 8.4.1 Adverse Event  
 8.4.4 Reporting of Exposure to 
COVID -19 (SARS -CoV -2 
 9.5.2 Safety Analyses  Updated instructions on recording 
COVID -19 vaccination data  and 
reporting COVID -19-associated AEs  Updated for clarity of 
instructions  
 8.4.1.1 Serious Adverse Event 
Reporting  Added overdose  Added for completeness of list  
 9.5.2 Safety Analyses  Added text that descriptive statistics 
would be provided for ECG  Updated for completeness  
 Table 10.1 Clinical Laboratory 
Tests  Updated Table 10.1  
 Remove d bicarbonate test  
 Update d creatinine clearance to be 
defined by Cockcroft -Gault 
equation  
 Require d PTT only if aPTT isn’t 
collected  
 Require d FSH and  TSH at 
Baseline -only Removed bicarbonate as being 
unnecessary for this indication 
and updated other language 
for clarity of instructions  
 10.3.2 CYP3A4 Inhibitors and 
Inducers  Clarified that list of CYP3A4 inhibitors 
and inducers is not complete  Added lan guage for accuracy 
and completeness  
 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 7 TABLE OF CONTENTS  
INVESTIGATOR AGREEME NT................................ ................................ ................................ ...2 
DOCUMENT HISTORY ................................ ................................ ................................ ................. 3 
SUMMARY OF CHANGES  ................................ ................................ ................................ ........... 4 
1. PROTOCOL SUMM ARY  ................................ ................................ .............................. 13 
1.1. Protocol Synopsis  ................................ ................................ ................................ ............ 13 
1.2. Study Schema  ................................ ................................ ................................ .................. 18 
1.3. Schedule of  Events  ................................ ................................ ................................ .......... 19 
2. INTRODUCTION  ................................ ................................ ................................ ........... 27 
2.1. Background  ................................ ................................ ................................ ...................... 27 
2.1.1.  Tenosynovia l Giant Cell Tumor (TGCT)  ................................ ................................ ........ 27 
2.1.2.  Pexidartinib (PLX3397)  ................................ ................................ ................................ ..27 
2.2. Study Rationale  ................................ ................................ ................................ ............... 28 
2.3. Benefit  and Risk Assessment  ................................ ................................ .......................... 29 
3. OBJECTIVES, OUTCOME MEASURES, AND ENDPOI NTS  ................................ ....30 
3.1. Rationale for Selection of Primary and Key Secondary Endpoints  ................................ 31 
4. STUDY DESIGN  ................................ ................................ ................................ ............ 32 
4.1. Over all Design  ................................ ................................ ................................ ................. 32 
4.1.1.  Design Overview  ................................ ................................ ................................ ............. 32 
4.1.2.  End of Study  ................................ ................................ ................................ .................... 33 
4.1.3.  Dose Regimen  ................................ ................................ ................................ ................. 33 
4.1.4.  Duration  ................................ ................................ ................................ ........................... 34 
4.2. Rationale for  Study Design  ................................ ................................ ............................. 34 
4.3. Justification for Dose  ................................ ................................ ................................ .......34 
5. STUDY POPULATION  ................................ ................................ ................................ ..35 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ............. 35 
5.2. Exclusion Criteria  ................................ ................................ ................................ ............ 35 
5.3. Screening Failures, Rescreening, and Subject Replacement  ................................ ........... 36 
6. STUDY TREATMENT(S)  ................................ ................................ .............................. 37 
6.1. Study Drug (s) Description  ................................ ................................ ............................... 37 
6.2. Preparation, Handling, Storage, and Accountability for Study Drug(s)  .......................... 37 
6.2.1.  Preparation, Handling, and Disposal  ................................ ................................ ............... 37 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 8 6.2.2.  Administration  ................................ ................................ ................................ ................. 37 
6.2.3.  Storage  ................................ ................................ ................................ ............................. 38 
6.2.4.  Drug Accountability  ................................ ................................ ................................ ........ 38 
6.3. Measure to Minimize Bias:  Randomization and Blinding  ................................ ............. 38 
6.4. Treatment Compliance  ................................ ................................ ................................ ....38 
6.5. Guidelines for Dose Modification  ................................ ................................ ................... 39 
6.5.1.  Renal Impairment  ................................ ................................ ................................ ............ 41 
6.6. Prior and Concomitant Medications  ................................ ................................ ................ 42 
6.6.1.  Analgesic Use  ................................ ................................ ................................ .................. 42 
6.7. Prohibited Therapies/Products  ................................ ................................ ......................... 42 
6.7.1.  Hormonal Contraceptives  ................................ ................................ ................................ 43 
6.7.2.  Acid -reducing Agents  ................................ ................................ ................................ ......43 
7. STUDY DRUG DISCONTIN UATION AND DISCONTINUATION  FROM 
THE STUDY  ................................ ................................ ................................ ................... 44 
7.1. Subject Withdrawal/Discontinuation from the Study  ................................ ...................... 44 
7.2. Lost to Follow -up ................................ ................................ ................................ ............ 45 
8. STUDY PROCEDURES  ................................ ................................ ................................ .46 
8.1. Eligibility Assessment  ................................ ................................ ................................ .....46 
8.2. Enrollment  ................................ ................................ ................................ ....................... 46 
8.3. Efficacy Assessments  ................................ ................................ ................................ ......47 
8.3.1.  Response Assessment  ................................ ................................ ................................ ......47 
8.3.2.  Patient Reported Outcomes  ................................ ................................ ............................. 47 
8.3.3.  Radiographic Tumor Assessments  ................................ ................................ .................. 47 
8.4. Safety Assessments  ................................ ................................ ................................ ......... 48 
8.4.1.  Adverse Event  ................................ ................................ ................................ ................. 48 
8.4.1.1.  Serious Adverse Events Reporting  ................................ ................................ .................. 49 
8.4.1.2.  Adverse Events of Special Interest  ................................ ................................ .................. 50 
8.4.2.  Pregnancy/Embryo -Fetal Toxicity  ................................ ................................ .................. 51 
8.4.3.  Clinical Laboratory Evaluations  ................................ ................................ ...................... 52 
8.4.4.  Reporting of Exposure to COVID -19 (SARS -CoV -2) ................................ .................... 52 
8.4.5.  Other Safety  ................................ ................................ ................................ ..................... 53 
8.5. Pharmacok inetic (PK) Assessment (s) ................................ ................................ ............. 53 
8.6. Pharmacodynamic Assessment (s) ................................ ................................ ................... 53 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 9 9. STATISTICAL  CONSIDERATIONS  ................................ ................................ ............ 54 
9.1. General Statistical Considerations  ................................ ................................ ................... 54 
9.2. Statistical Hypothesis  ................................ ................................ ................................ ......54 
9.3. Sample Size Determination  ................................ ................................ ............................. 54 
9.4. Population for Analysis Sets  ................................ ................................ ........................... 54 
9.5. Statistical Analysis  ................................ ................................ ................................ .......... 54 
9.5.1.  Efficacy Analyses  ................................ ................................ ................................ ............ 55 
9.5.1.1.  Primary Efficacy Analyses  ................................ ................................ .............................. 55 
9.5.1.2.  Secondary Efficacy Analyses  ................................ ................................ .......................... 55 
9.5.1.3.  Exploratory Analyses  ................................ ................................ ................................ ......55 
9.5.1.4.  Multiplicity Adjustment  ................................ ................................ ................................ ..55 
9.5.2.  Safety Analyses  ................................ ................................ ................................ ............... 55 
9.5.3.  Other Analyses  ................................ ................................ ................................ ................ 57 
9.6. Interim Analyses  ................................ ................................ ................................ .............. 57 
10. APPENDICES – SUPPORT ING DOCUMENTATION AN D OPERATIONAL 
CONSIDERATIONS  ................................ ................................ ................................ ......58 
10.1.  Appendix 1:  Regulatory and Ethical Considerations  ................................ ..................... 58 
10.1.1.  Regulatory Compliance  ................................ ................................ ................................ ...58 
10.1.2. Informed Consent  ................................ ................................ ................................ ............ 59 
10.1.3.  Subject Confidentiality  ................................ ................................ ................................ ....60 
10.1.4.  Data Integrity and Quality Assurance  ................................ ................................ ............. 60 
10.1.5.  Committees  ................................ ................................ ................................ ...................... 61 
10.1.6.  Study Documentation and Storage  ................................ ................................ .................. 62 
10.1.7.  Finances  ................................ ................................ ................................ ........................... 63 
10.1.8.  Publication and Public Disclosure Policy  ................................ ................................ ........ 63 
10.1.9.  Protocol Deviations  ................................ ................................ ................................ ......... 64 
10.1.10.  Study and Site Closure  ................................ ................................ ................................ ....64 
10.1.11.  Product Complaints  ................................ ................................ ................................ ......... 64 
10.2.  Appendix 2:  Laboratory Assessments  ................................ ................................ ............ 65 
10.3.  Appendix 3:  Reference Standards  ................................ ................................ .................. 66 
10.3.1.  Cockcroft -Gault Equation  ................................ ................................ ............................... 66 
10.3.2.  CYP3A4 Inhibitors and Inducers  ................................ ................................ .................... 66 
10.4.  Appendix 4:  Response Criteria  ................................ ................................ ....................... 69 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 10 10.5.  Appendix 5:  General Information – Adverse Events  ................................ ..................... 76 
10.5.1.  Definition of Adverse Event  ................................ ................................ ............................ 76 
10.5.2.  Serious Adverse Event  ................................ ................................ ................................ ....77 
10.5.3. Grade Assessment  ................................ ................................ ................................ ........... 78 
10.5.4.  Causality Assessment  ................................ ................................ ................................ ......78 
10.5.5.  Action Taken Regarding Study Drug (s) ................................ ................................ .......... 79 
10.5.6.  Other Action Taken for Event  ................................ ................................ ......................... 79 
10.5.7.  Adverse Event Outcome  ................................ ................................ ................................ ..79 
10.6.  Appendix 7:  Patient Reported Outcomes  ................................ ................................ .......80 
10.6.1.  PROMIS Physical Function Scale  ................................ ................................ ................... 80 
10.6.2.  PROMIS Item Bank v. 1.2 – Physical Functioning (Upper Extremity)  .......................... 82 
10.6.3.  EQ-5D-5L ................................ ................................ ................................ ........................ 84 
11. REFERENCES  ................................ ................................ ................................ ................ 87 
12. LIST OF ABBREVIATION S ................................ ................................ ......................... 88 
 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 11 LIST OF TABLES  
Table  1.1: Schedule of Events:  Treatment Continuation Cohort  ................................ ................ 19 
Table  1.2: Schedule of Events:  Treatment -Free Period of Treatment -Free/Re -
Treatment Cohort  ................................ ................................ ................................ ........ 22 
Table  1.3: Schedule of Events:  Re -Treatment Perioda of Treatment -Free/Re -Treatment 
Cohort  ................................ ................................ ................................ ......................... 24 
Table  3.1: Description of Objectives, Outcome Measures, and Endpoints (Treatment -
Free/Re -Treatment Cohort)  ................................ ................................ ........................ 30 
Table  3.2: Description of Objectives, Outcome Measures, and Endpoints (Treatment 
Continuation Cohort)  ................................ ................................ ................................ ..31 
Table  6.1: Study Drug Dosing Information  ................................ ................................ ................. 37 
Table  6.2: Recommended Dose Reductions for  Pexidartinib for Adverse Reactions  ................. 39 
Table  6.3: Recommended Dosage Modifications for Pexidartinib for Adverse Reactions  ......... 39 
Table  6.4: Additional Liver Evaluation  ................................ ................................ ....................... 40 
Table  6.5: Recommended Dosage Reductions for Pexidartinib for Concomitant Use of 
Strong CYP3A Inhibitors or UGT Inhibitors  ................................ ............................. 43 
Table  10.1:  Clinical Laboratory Tests  ................................ ................................ ........................... 65 
Table  10.2:  CYP3A4 Inhibitors  ................................ ................................ ................................ .....67 
Table  10.3:  Best Overall Response When Confirmation of CR and PR Required  ........................ 74 
 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 12 LIST OF FIGURES  
Figure  1.1: Study Level Flow Diagram  ................................ ................................ ......................... 18 
 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Co nfidential  
Page 26 f Only subjects who end their study participation early with no radiologic disease progression will have an additional MRI at 3  months ± 14 days after their last 
dose of study treatment or before any new TGCT therapy, including sur gery, whichever occurs first. EOS will occur after this additional MRI.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 27 2. INTRODUCTION  
2.1. Background  
2.1.1.  Tenosynovial Giant Cell Tumor (TGCT)  
Tenosynovial giant cell tumor (TGCT) is a rare, nonmalignant neoplasm of the synovium, 
bursae, or tendon sheaths that is driven by overexpression of colony -stimulating factor -1 (CSF -1) 
often afflicting adults under 40 years of age.  Annual TGCT incidence i s estimated to be 43 cases 
per one million individuals, of which approximately 10% are of the diffuse subtype.  Surgical 
resection, when feasible, is the standard treatment for TGCT; however, recurrence of the diffuse 
subtype is particularly common.  Repea ted surgeries often result in increasing morbidity and 
functional limitations of the affected joints.  The diffuse disease often has more extensive 
involvement and a poorer likelihood of a successful cure with surgery, and therefore often may 
not be amenab le to surgical resection due to the risk of morbidity or high risk of recurrence in 
diffuse disease.  Systemic therapies targeting CSF -1 activity are being evaluated for the 
treatment of TGCT.  
2.1.2.  Pexidartinib (PLX3397)  
Pexidartinib is an oral small -molecule t yrosine kinase inhibitor that targets 3 kinases:  CSF-1 
receptor ([CSF -1R] or feline McDonough sarcoma [FMS] kinase); proto -oncogene receptor 
tyrosine kinase (c -Kit), and FMS -like tyrosine kinase 3. TURALIO™ (Pexidartinib) was 
approved, 02 Aug 2019, by the United States (US) Food and Drug Administration (FDA) for the 
treatment of symptomatic TGCT associated with severe morbidity or functional limitations and 
not amenable to improvement with surgery.  Pexidartinib is the first systemic therapy to  show a 
robust tumor response in TGCT with improved patient symptoms and functional outcomes; 
cholestatic hepatotoxicity has been identified as a risk.  It was approved with a boxed warning 
for hepatotoxicity and is available only through a restricted prog ram called the TURALIO Risk 
Evaluation and Mitigation Strategy (REMS) program.  
The approval was based on the durable overall response rate (ORR) observed in the Phase 3  
study PLX108 -10 (ENLIVEN ) which provided compelling evidence of its effectiveness for t he 
treatment of subjects with TGCT.   In the ENLIVEN study, an international, multicenter, 
randomized (1:1), double -blind, placebo -controlled study, 120 subjects with TGCT not amenable 
to surgical resection  and treated with  pexidartinib had a robust tumor r esponse rate versus  
placebo at Week 25 by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 
(39% vs 0%; P<0.0001) and by tumor volume score (TVS) (56% vs 0%; P<0.0001).  Further 
evidence of tumor response and clinical improvements are noted  in the TGCT extension cohort 
of Study PLX108 -01, as well as the longer -term data from the ENLIVEN study.  
The safety data showed serious adverse events ( SAEs ) occurred in 13% (8/61) of patients in the 
pexidartinib group and 2% (1/59) of patients in the pla cebo group.  The most frequent 
pexidartinib -associated treatment -emergent adverse events (TEAEs) were hair color changes, 
fatigue, aspartate aminotransferase  (AST)  increase, nausea, alanine aminotransferase (ALT) 
increase, and dysgeusia.  Pexidartinib was associated with 2 types of hepatic adverse reactions.   
The first was a dose -dependent, generally low -grade aminotransferase elevation related to the 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 28 CSF-1R inhibition mechanism of action.  These elevations are primarily observed during the first 
8 weeks of  treatment.  The second hepatic adverse reaction, mixed or cholestatic hepatotoxicity,  
which while rarely serious can be life -threatening,  also generally appeared in the first 8 weeks of 
treatment , however,  is uncommon and idiosyncratic in nature.  
As noted , long -term follow -up showed further increase s in tumor response with continued 
pexidartinib treatment.   For long -term pooled efficacy and safety, 130 patients  in ENLIVEN and 
PLX108 -01 received pexidartinib; 47% (61) patients remained on treatment at data cut -off.  
Median follow -up from first dose to data cutoff was 23 months (range, 16, 67); median treatment 
duration was 17 months (range, 1, 60+).  Four percent  (5) patients discontinued pexidartinib due 
to progressive disease  (PD) .  Pooled RECIST v1.1 -based best overall response (BOR) was 54%, 
with increased BOR from longer treatment.  The safety profile was consistent with earlier 
reports, with no new safety si gnals.  
Currently, besides the ENLIVEN and PLX108 -01 studies, there are 2 additional Phase 1/2 
studies  (Study PL3397 -A-A103  and Study PL3397 -A-U126) that are ongoing.  The objectives of 
these 4 pexidartinib studies in TGCT have been met and the investigatio nal sites are to be closed.   
Eligible subjects from these studies will be included in the subject population for this study . 
Refer to the Pexidartinib Investigator’s Brochure (IB) for additional details and information.  
2.2. Study Rationale  
Over time, with dail y treatment, many patients on long -term use of pexidartinib in these studies 
achieved significant tumor responses.  In the ENLIVEN study, with the 90 -day post -treatment 
observation period, no cases of rapid tumor regrowth  were observed , suggesting that qua rterly 
follow -ups are of adequate frequency to identify any patients, who need to re -initiate their 
treatment.  However, beyond the 3 -month post -treatment follow -up in ENLIVEN, there are no 
data to fully understand the impact of discontinuing pexidartinib treatment in patients with stable 
and/or residual disease.  And, with slow -growing disease like TGCT, 3 months is not sufficient  
to determine the time when the treatment needs to be restarted.  Feasibility of intermittent on -off 
dosing remains an open medic al question.   
Patients with TGCT diagnosed early in their lives face potentially several decades of daily 
treatment.  In the real -world setting, subjects and Investigators are faced with decisions 
surrounding patients’ activities of daily living and treat ment with pexidartinib for TGCT.  
Further data are necessary to fully understand the safe and effective discontinuation and re -
treatment with pexidartinib therapy in this patient population.  
The purpose of this Phase 4 multicenter study in subjects with TGCT previously treated with 
pexidartinib are two -fold.  At the Screening visit/time of consent, the Investigators and subjects 
are provided the choice to either continue treatment with pexidart inib or discontinue treatment 
with the possibility of re-initiat ing pexidartinib treatment at a later time.  Findings from this 
study will provide important prospective discontinuation and re -treatment data with pexidartinib 
in previously treated  subjects with residual disease.  
Ultimately, this study will contribute meaningful information to the body of research on 
pexidartinib treatment for patients with TGCT and the safe and effective discontinuation and re-
treatment with pexidartinib therapy . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 29 2.3. Benefit and  Risk Assessment  
As note d, in the Pexidartinib Clinical Development Program, pexidartinib has demonstrated 
statistically significant and clinically meaningful efficacy.  The efficacy data from the ENLIVEN 
study provide evidence of its effectiveness for the  treatment of subjects with TGCT .  Further 
evidence of tumor response and clinical improvement s are noted in the TGCT extension cohort 
of the PLX108 -01, as well as the longer -term data from the ENLIVEN study .6  The benefits  for 
subjects treated with pexidartinib in these  studies is expected to continue to be observed in this 
study.  
Pexidartinib can cause hepatic adverse reactions, including aminotransferase  abnormalities or 
mixed or cholestatic hepatotoxicity  that may be fatal .  Hepatotoxicity is an important adverse 
drug reaction ( ADR ).  Serious and prolonged hepatotoxicity with ductopenia and/or cholestasis 
has been observed in subjects tre ated with pexidartinib.  Cases of cholestasis have been observed 
in the first 8 weeks and have generally resolved with treatment discontinuation, but in some 
cases have been severe, with a protracted course requiring, in 1 case, transplantation.  The 
mecha nism of cholestatic hepatotoxicity is unknown, and its occurrence cannot be predicted.  
Also, guidance on protocol -defined dose reductions, discontinuation of pexidartinib, increased 
frequency of laboratory monitoring, and reporting of findings have been es tablished.  After  
re-initiating treatment with pexidartinib the liver  function  tests AST, ALT, total bilirubin, direct 
bilirubin, alkaline phosphatase ( ALP ), and gamma -glutamy l transfera se (GGT) will be monitored 
weekly for the first 8 weeks, every 2 weeks  for 1 month , and every 3 months thereafter.  The 
dose of pexidartinib will be reduced, withheld or permanently discontinued based on the severity 
of hepatoxicity.  Re-challenge with pexidartinib is not to be attempted without prior discussion 
with the Sponsor’s Medical Monitor.  
Re-challenges with a reduced dose of pexidartinib may result in a recurrence of increased serum 
transaminases, bilirubin, or ALP.  The mixed or cholestatic hepatotoxicity is idiosyncratic and 
may therefore recur with re -challenge .  Therefore, liver function tests are to be monitored weekly 
for the first 2 month s after re -challenge , then every 2 weeks for 1 month , and then once every 3 
months or more frequently as directed by the Investigator .  Both the Investigator and subjects 
will be educated by the Sponsor on the eligibility criteria , benefits/risks of pexidartinib , 
necessary liver monitoring testing and guidance on dose reduction , and discontinuation.  
In addition, administration with food increases pexidartinib exposure by 100% and may increase 
the risk of hepatotoxicity.  Therefore, Investigators and subjects are instructed that pexidartinib 
administration is to be on an empty stomach, at least 1 hour before or 2 hours after a meal or 
snack.  Investigators and s ubjects will also be instructed to avoid concomitant use of pexidartinib 
with strong cytochrome P450 ( CYP )3A inhibitors or uridine 5' -diphospho -
glucuronosyltransferase ( UGT ) inhibitors during the study.  
Refer to the Pexidartinib  IB for additional details and information . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 32 4. STUDY DESIGN  
4.1. Over all Design  
This is a Phase 4, multicenter  study in subjects with TGCT ( pigmented villonodular synovitis 
[PVNS ] or giant cell tumor of the tendon sheath [ GCT -TS]) who were previously treated with 
pexidartinib in one of the following studies  (hereafter referred to as prior study) : (PLX108 -10 
(ENLIVEN), PLX108 -01, PL3397 -A-A103, and PL3397 -A U126).  Based on these prior studies, 
subjects will be enrolled from investigational sites in the US, European Union ( EU) 
(Netherlands, Spain, Hungary, and Italy), Australia, and Taiwan .  The s ubject population is 
described in Section  5. 
The study start date is the date when the first subject has signed an informed consent and the 
study end date will be the completion of the last patient ’s Follow -up Visit .  A subject is eligible 
to be enrolled into the study when the Investigator  or designee has determined the subject  is 
currently receiving pexidartinib treatment as part of one of the prior studies and meets  the 
inclusion/exclusion criteria for this study  (Section  5). 
4.1.1.  Design Overview  
Subjects in the 4 ongoing TGCT studies will be screened at the “ End-of-Treatment  (EOT) visit” 
(i.e., the visit at which they receive their final dose of pexidartinib) of their previous study , at 
which time they can elect to enroll in the PL3397 -A-U4003 stu dy in 1 of 2 cohorts – the 
Treatment Continuation Cohort  (where their existing pexidartinib treatment will continue 
uninterrupted) or Treatment -Free/ Re -Treatment Cohort  (where they will discontinue 
pexidartinib treatment with the possibility to re -initiat e treatment over the course of the study).   
Subjects who elect to not enroll in the PL3397 -A-U4003 study will remain in their current study 
and complete their respective End-of-Study activities.  
Subjects who elect to enroll in PL3397 -A-U4003 will sign an institutional review board 
(IRB)/independent ethics committee (IEC) -approved informed consent form  (ICF) .  By signing 
the ICF, subjects will permit acquisition and data transfer  of any data collected in their precursor 
study, including, but not limited to, medical and surgical history, and prior medications.  The 
assessments performed during the preceding study’s End -of-Treatment visit will serve as the 
Baseline measurements for the PL3397 -A-U4003 study.  
Eligible s ubject who choose to continue pexidartinib treatment in  the Treatment Continuation 
Cohort  will remain on their current dosage regimen of pexidartinib and undergo clinical 
assessments at 3-month intervals  for the duration of the study.  
Subjects who choose to discontinue pexidartinib will be enrolled  in the Treatment -Free period of 
the Treatment -Free/Re -Treatment Cohort .  These subjects will stop pexidartinib dosing at 
entry  into PL3397 -A-U4003 (i.e., after their final dose at the preceding study’s EOT  visit) .  
Subjects will undergo clinical assessments 1 month after enrollment, 3 months after enrollment, 
and then at 3-month intervals .  Subjects will remain treatment -free until retreated with 
pexidartinib, based on the Investigator and /or subject’s discretion.  Considerations are given to 
tumor response, subjective and/or functional measures , and safety  parameters in the decision -
making process .  The r ationale for discontinuation and re-treatment  with pexidartinib will be 
recorded accordingly.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 33 For subjects who restart pexidartinib t reatment  in the Re -Treatment period of the Treatment -
Free/Re -Treatment Cohort , pexidartinib will be administered at the dosage level  at which the 
subject completed the prio r study.   Doses must be administered on an empty stomach (at least 
1 hour before or 2 hours after a meal  or snack ), at approximately the same times of the day , and 
approximately 12  hours apart.  The full set of study assessments will be performed (Baseline -2).  
During re -treatment, Investigat ors will ensure weekly liver monitoring tests for the first 8 weeks, 
then every 2 weeks for the next month, then every 3 months or more  frequently  as directed by 
the Investigator  (see Table  6.3). 
The Investigator will evaluate the quarterly  magnetic resonance imaging ( MRI ) scans to perform 
a qualitative tumor assessment (i.e., stable disease) for subjects in th e Treatment -Free/Re -
Treatment Cohort .  Additional assessments may be conducted based on worsening of tumor 
response  as deemed necessary by the Investigator .  For those s ubjects who restart pexidartinib 
treatment in the Re -Treatment period of the Treatment -Free/Re -Treatment Cohort , the 
response should note “Progression” and the a ssessments after re -treatment should use Baseline 2  
as the reference to determine Progression or Non -Progression . 
The PRO s (PROMIS  PF and EQ -5D-5L) will be performed every 3 months for all subjects . 
Ongoing safety  will include  serum chemistry, hematology, urinalysis , coagulation,  ECG,  
hormone testing , and physical examination , and subjects will be monitored for adverse events 
(AEs)/ TEAEs . 
Subjects on treatment who end their study participation early with no radiologic disease 
progression will undergo a final MRI 3 months  ± 14 days after their last dose of study treatment  
or before any new TGCT therapy, including surgery.  
Subjects who discontinue early from the s tudy will complete the End-of-Study ( EOS )/EOT visit 
and will be withdrawn from the study.  
The subject population is described in Section  5.  A flow diagram of the study is  presented in  
Figure  1.1. 
4.1.2.  End of Study  
The primary comple tion date is the date when the last of those subject (s) entering the 
Treatment -Free period of the Treatment -Free/Re -Treatment Cohort  either progress es to and 
completes  the Re-Treatment period and/or remains treatment -free for the duration of the study .  
This date is used as the cut -off date for the analysis of the primary efficacy endpoint(s) of the 
study.  
The overall end of the study w ill occur when the last subject has their last visit/contact . 
The subject’s EOS is the date of their last study visit/con tact. 
4.1.3.  Dose Regimen  
Pexidartinib will be provided as an oral, daily administration at the dosage level at the end of 
their prior study.  Doses will be taken on an empty stomach (at least 1 hour before or 2 hours 
after a meal  or snack ), at approximately the same times of the day , and approximately 12-hours 
apart . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 34 Note:  Dose escalation of pexidartinib treatment is not permitted during the course of this study . 
4.1.4.  Duration  
The study start date is the date when the first subject sign s the ICF  and the study continu es until 
the last subject has had their last visit.  
Duration of Treatment and Subject Participation  
Subjects will be evaluated for eligibility at the last visit of their prior study.  
Subject in the Treatment Continuation Cohort  will undergo study assessments at 3-month 
intervals for a maximum of 24 months.  
Subjects in the Treatment -Free period of  the Treatment -Free/Re -Treatment Cohort  will 
undergo study assessments at 1 month after enrollment, 3 months after enrollment, and then at 
3-month intervals until either re-treatment with pexidartinib  or for a maximum of 24 months . 
Subjects in the Re-Treatment period of the Treatment -Free/Re -Treatment Cohort  will 
undergo study assessments at M1, M2 and then at 3-month intervals .  The maximum duration for 
any subject with in the combined periods of the Treatment -Free/Re -Treatment Cohort  is 
24 months .  Liver safety assessment s will follow a separate schedule  (See Table  1.3). 
The study will end with the last subject’s last visit.  A post -trial access plan, delineating options 
for access to pexidartinib, will be available for subjects after completing their study participation 
if the subject is benefiting from the study drug . 
Overall Study Duration  
Anticipated total duration of the study is expected to be approximately 24 months.  See 
Section  4.1 for the definition of study start and Section  4.1.2  for the definition of the overall 
EOS.  
Study Drug Continuation After the End of Study  
A post -trial access plan , delineating options for access to pexidartinib, will be available for 
subjects after completing their study participation if the subject is benefiting from the study drug.  
4.2. Rationale for  Study Design  
This Phase 4 study design assumes that in subjects with TGCT , having stable disease and who 
are being  treated with pexidartinib , it is possible to suspend treatment until there are signs of 
disease progression.  It is assumed that re -initiation of treatmen t with pexidartinib will again lead 
to stabilization of the subject 's disease and potentially to a diminution of the disease.  
4.3. Justification for Dose  
The dose used during the subject’s prior study  was found to be safe and effective for the subject.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 35 5. STUDY POPULATION  
5.1. Inclusion Criteria  
Subjects must meet all of the following criteria to be eligible for enrollment into the study:  
1. Currently enrolled and have not been discontinued from pexidartinib treatment  in one of 
the following studies: Study PLX108 -10 (ENL IVEN), Study PLX108 -01, Study PL3397 -
A-A103, or Study PL3397 -A-U126 . 
2. Willing and able to complete the PROMIS (Physical Function Scale)  and EQ-5D-5L 
(European Quality of Life)  throughout the study.  
3. Willing and able to provide written informed consent form (ICF) prior to any study -
related procedures and to comply with all study requirements.  
4. Females of reproductive potential must have a negative urine pregnancy test at 
Screening/Baseline (to be confirmed by a serum pregnancy test taken on the End -of-
Treatment visit of their prior study) and should be advised to use an effective, non -
hormonal method of contraception during treatment with pexidartinib and for 1 month 
after the last dose.  Males with female partners of reproductive potential should be 
advis ed to use an effective method of contraception during treatment with pexidartinib 
and for 1 month after the last dose.   Female partners of male patients should concurrently 
use effective contraceptive methods (hormonal or non -hormonal).  
Note :  A female is considered of reproductive potential following menarche and until 
becoming postmenopausal (no menstrual period for a minimum of 12 months) unless 
permanently sterile (undergone a hysterectomy, bilateral salpingectomy or bilateral 
oophorectomy) with a confi rmed by follicle stimulating hormone (FSH) test level 
>40 mIU/mL.  
5. Male subjects must not freeze or donate sperm starting at Screening and throughout the 
study period, and for at least 5 half-lives or 1 month after the final study drug 
administration , which ever is longer . 
Female subjects must not donate, or retrieve for their own use, ova from the time of 
Screening and throughout the study treatment  period, and for at least 1 month or 
5 half-lives after the final study drug administration , whichever is longer . 
5.2. Exclusion Criteria  
Subjects who meet any of the following criteria are NOT  eligible  for enrollment into the study  
1. Subject has a clinically significant abnormality identified by the Investigator at Screening 
on physical examination, laboratory tests, or electrocardiogram which, in the judgement 
of the Investigator, would preclude the subject’s safe completion of the study .  
2. Exposure to another investigational drug  or current participation in other  therapeutic 
investigational procedures, besides pexidartinib studies , within 1 month  prior to start of 
study treatment .  Any known contraindication to treatment with, including 
hypersensitivity to, the study drug(s)  or excipients in pexidartinib.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 36 5.3. Screening Failures, Rescreening, and Subject Replacement  
If a s ubject  does not meet eligibility criteria at Screening, they may be rescreened based on the 
Investigator’s discretion .  Details will be included in the PL3397 -A-U4003 Study Manual . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 37 6. STUDY TREATM ENT(S)  
See Figure  1.1 for treatment sequence.  
6.1. Study Drug (s) Description  
Table  6.1 describes the formulation, dose, regimen, duration, packaging, and labeling of 
pexidartinib . 
Table  6.1: Study Drug Dosing Information  
Study Drug Name  Pexidartinib  
Dosage Formulation  200 mg capsule s 
Dosage Level(s)  The dose level at end of prior study  will serve as the starting dose level . 
Note:  Dose escalation of pexidartinib treatment is not permitted  during the 
course of this study . 
Route of Administration  Oral 
Dosing  Pexidartinib should be administered twice daily approximately 12 h apart on an 
empty stomach (at least 1 hour before or 2 hours after a meal  or snack ). 
Duration  Daily until subject’s end of st udy 
Packaging  PLX3397 -HCl 200 mg capsules are manufactured, packaged, and labeled 
according to Good Manufacturing Practices and Good Clinical Practices (GCP) . 
Packaging will clearly display the name of product, storage condition, and other 
required information as applicable in accordance with local regulations . 
Labeling  Packaging  will be labeled as required per local regulatory requirement . 
6.2. Preparation, Handling, Storage, and Accountability for Study 
Drug(s)  
6.2.1.  Preparation, Handling, and Disposal  
All pexidartinib is supplied as 200-mg capsules that need no further preparation at the study 
sites.  
Procedures for proper handling and disposal should be followed in compliance with the Standard 
Operating Procedures (SOP s) of the Investigational site. 
6.2.2.  Administration  
Pexidartinib is prov ided as 200-mg capsules for oral, daily administration.  Subjects are to be 
administered the dosage level at which they completed their prior study.   Doses must be 
administered on an empty stomach (at least 1 hour before or 2 hours after a meal  or snack ), at 
approximately the same times of the day , and approximately 12 hours apart.  Administration with 
food (particularly with high proportion of fat) may result in increased exposure to pexidartinib 
and should be avoided.  Dose reductions  and interruptions ar e permitted according to pre -
specified guidelines.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 38 On the day of the scheduled visit, s ubjects will be instructed to take their morning and evening 
dose at the usual time of study treatment.  Subje cts should be told to bring their bottle containing 
all unused study treatment to the clinic for account ability.  
Between clinic visits, subjects will administer their study treatment at home and record the 
dosing information in the study dosing Diary.  Missed doses (those generally outside of a 
± 2-hour dosing window) should be skipped and NOT  administered as a double dose at the next 
dosing time point.  Subjects who vomit their dose should be instructed NOT  to make up that 
dose.   Study sites will call subjects on a weekly basis as reminders to br ing IP bottles to site 
visits and to complete their diaries.  During these calls, study sites may also collect other 
information, including AEs and concomitant medications.  
Further details on study treatment administration are contained in the PLX3397 -A-U4003 
Pharmacy Manual . 
6.2.3.  Storage  
Pexidartinib should be stored at the sites in a secure , controlled facility and only provided to 
subjects who signed an ICF  and are participating in the study.  Pexidartinib 200 mg capsules 
should be stored at controlled room t emperature (should not be stored above 25°C/77°F).  
Excursions are permitted to 15°C to 30°C (59ºF to 86ºF) .  If storage conditions are not 
maintained per specified requirements, then the Sponsor or contract research organization (CRO) 
should be contacted.   Subjects will be instructed to store pexidartinib  at room temperature out of 
the reach of children or other cohabitants.  
6.2.4.  Drug Accountability  
When a drug shipment is received, the Investigator  or designee will check the amount and 
condition of the drug against the shipping documentation.  
Documentation of receipt of shipment  should be return ed as instructed on the form.  The original 
will be retained at the study site . 
In addition, the Investiga tor or designee shall contact the Sponsor or designee as soon as possible 
if there is a problem with the shipment.  
The Investigator  is responsible for study drug accountability, reconciliation , and record 
maintenance ( i.e., documentation of receipt of ship ment , dispensation/return record, and 
certificate of destruction/return receipt).  
Additional information can be found in the PL3397 -A-U4003 Study Manual . 
6.3. Measure to Minimize Bias:  Randomization and Blinding  
Not applicable.  
6.4. Treatment Compliance  
Dosing compliance for pexidartinib will be assessed by means of capsule counts remaining or 
bottles returned.  All pexidartinib packaging will be returned at each subject visit; an accounting 
of capsules will be made and recorded in the electronic case rep ort form ( eCRF ).  If zero 
capsules were returned, subjects are asked  whether any were disposed/thrown away, rather than 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 39 taken orally, and this information will be recorded in the eCRF.  Subjects will record time and 
day of administration in the subject’s Diary. 
6.5. Guidelines for Dose Modification  
Reduction or interruption of the dose for toxicity may take place at any time according to the 
guidelines in  Table  6.3.  Dose reduction/interruption guidelines for hematologic and non -
hematologic treatment -related TEAEs are based on severity.  Dose interruptions can be 
implemented at the discretion of the treating physician to manage intolerable or clinically 
significa nt toxicity.  If a dose interruption is required, study assessments should be performed as 
scheduled, irrespective of the study treatment delay.  Interruptions due to toxicity lasting 
>14 days require treatment discontinuation unless the Medical Monitor approves continuation.  
The recommended dose reductions for  AEs are provided in Table  6.2. 
Table  6.2: Recommended Dose Reductions for Pexidartinib for Adverse Reactions  
Dose Reductio n  New Total Daily Dose  Administration of Total Daily Dose  
First 600 mg  200 mg in the morning and 400 mg in the evening  
Second  400 mg  200 mg twice daily  
Subjects unable to tolerate 200 mg orally twice  daily  will be discontinued.  Once dose reduction 
takes place for toxicity, a dose re -escalation is not allowed.  
The recommended dosage of pexidartinib for patients with mild to severe renal impairment 
(creatinine clearance [ CrCL] 15 to 89 mL/min estimated by Cockcroft -Gault using actual body 
weight , Section 10.3.1 ) is 200 mg in the morning and 400 mg in the evening.  
Dose -modification guidelines for treatment -emergent toxicities as well as guidelines fo r their 
management are presented in  Table  6.3.  These parameters are only a guide and are not intended 
to supersede the clinical judgment of the treating physician.  All adjustments should be 
communicated to the Sponsor’s Medical Monitor or designee.   Re-challenge with a reduced dose 
of pexidartinib may result in a recurrence of increased serum transaminases, bilirubin, or ALP.   
Investigators will ensure weekly liver monitoring tests for the first 8 weeks after re -challenge, 
then every 2 w eeks for the next month, then every 3  months or more frequently as directed by 
the Investigator.  
Additional information can be found in the  PL3397 -A-U4003 Study Manual  and the Pexidartinib 
IB. 
Table  6.3: Recommended Dosage Modifications for Pexidartinib for Adverse Reactions  
Event  Severity  Pexidartinib Dosage Modifications  
Hepatoxicity  
Increased ALT 
and/or AST  >3 to 5 × ULN   Withhold and monitor liver tests weekly.  
 If AST and ALT ≤3 × ULN within 4 weeks, resume at 
reduced dose.  
 If AST or ALT not ≤3 × ULN in 4 weeks, permanently 
discontinue pexidartinib.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 40 Event  Severity  Pexidartinib Dosage Modifications  
>5 to 10 × ULN   Withhold and monitor liver tests twice weekly.  
 If AST and ALT ≤3 × ULN within 4 weeks, resume at 
reduced dose.  
 If AST or ALT not ≤3 × ULN in 4 weeks, permanently 
discontinue pexidartinib.  
>10 × ULN   Permanently discontinue pexidartinib.  
 Monitor liver tests twice weekly until AST or ALT ≤5 × 
ULN, then weekly until ≤3 × ULN.  
Increased 
ALPa and 
GGT  ALP >2 × ULN with GGT 
>2 × ULN   Permanently discontinue pexidartinib.  Monitor liver tests 
twice weekly until ALP ≤5 times ULN, then weekly until 
≤2 × ULN.  
Increased 
bilirubin  TB >ULN to <2 × ULN  
or 
DB >ULN and <1.5 × ULN   Withhold and monitor liver tests twice weekly.  
 If an alternate cause for increased bilirubin is confirmed 
and bilirubin <ULN within 4 weeks, resume at reduced 
dose.  
 If bilirubin not <ULN in 4 weeks, permanently discontinue 
pexidartinib.  
TB ≥2 × ULN  
or 
DB >1.5 × ULN   Permanently discontinue pexidartinib.  
 Monitor liver tests twice weekly until bilirubin ≤ULN.  
Adverse Reactions or Other Laboratory Abnormalities  
Any Severe or intolerable   Withhold until improvement or resolution.  
 Resume at a reduced dose upon improvement or resolution.  
ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase; DB = direct 
bilirubin; GGT = gamma -glutamyl transferase; TB = total bilirubin; ULN = upper limit of normal.  
a Confirm ALP elevations as liver isozyme fraction.  
Source:  Pexidartinib Study Manual  
Table  6.4: Additional Liver Evaluation  
Evaluation * Comments  
Increase frequency of testing liver chemistries to twice 
per week, including INR  and albumin , and continue 
until liver chemistries have stabilized, and then reduce 
to weekly until liver chemistries return to normal or 
baseline  Investigational treatment  may be started after liver 
function tests recover to Grade 0 to 1 or baseline level, 
and in consultation with Medical Monitor  
Detailed history focusin g on medications and 
substances used: alcohol, change in medication 
dosages, new medications added, attention to use of 
acetaminophen, OTC medication use and recreational 
drug use. Check for change in diet or use of dietary 
supplements, with particular att ention to dose and 
duration of any herbal product  Suspect medications will be discontinued or substituted 
for if possible  
Detailed medical history and physical exam seeking 
new abnormalities  Evaluate abnormalities found  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 41 Evaluation * Comments  
Full serological evaluation for he patitis A, B, C and E 
(IgG and IgM). Check for autoimmune hepatitis with 
serological laboratory studies  If viral hepatitis or autoimmune hepatitis suggested, 
have subject evaluated by hepatologist  
Liver ultrasound performed to evaluate liver and 
biliary tree Evaluate any abnormalities found  
Check history for exposure to chemical agents  Remove chemical exposure and have subject seen by 
hepatologist  
Obtain hepatology consult if liver function continues to 
rise beyond 14 days  Contact Medical Monitor  
Ig = immunoglobulin; INR  = international normalized ratio; OTC  = over-the-counter.  
*Cases are to be discussed with the Medical Monitor whenever investigational product  is being held for liver 
function test abnormality.  
All dose modifications (interruption,  delay, reduction, and/or discontinuation) should be based 
on the worst preceding toxicity ( National Cancer Institute -Common Terminology Criteria for 
Adverse Events [ NCI-CTCAE ] version 5.0) as shown in  Table  6.3.  Dose increases are  not 
permitted for pexidartinib .  Dose modification decisions may be based on laboratory results.  
Once the dose of pexidartinib  has been reduced because of toxicity, all su bsequent cycles should 
be administered at that lower dose level unless further dose reduction is required.  More than 
2 dose reductions are not allowed and if toxicity continues after 2 dose reductions, the subject 
will be withdrawn from the study treatmen t if further toxicity meeting the requirement for dose 
reduction occurs.  
For Grade 3 or Grade 4 events, monitoring (including local laboratory tests when appropriate) 
should be performed frequently and at an interval no greater than 7 days until the AE is 
determined to be resolving.  
6.5.1.  Renal Impairment  
A reduced dose of 600 mg/day (200 mg in the morning and 400 mg in the evening) is 
recommended in study subjects with mild to severe renal impairment (creatinine clearance 
[CrCL ] 15 to 89 mL/min estimated by Cockcroft -Gault using actual body weight).  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 42 6.6. Prior and Concomitant Medications  
During the study, if the use of any concomitant treatment becomes necessary ( e.g., for treatment 
of an AE), the treatment must be recorded on the source document and eCRF, includi ng the 
reason for treatment, name of the drug, dosage, route, and date of administration.  All 
medications including prescription, over-the-counter  (OTC), herbal and other nutritional 
vitamins and/or supplements taken within 30 days of the Baseline visit w ill be recorded on the 
eCRF.   Note that vaccinations for COVID -19 are to be recorded on the source document and 
captured on the eCRF under both the concomitant medications section and on the COVID -19 
forms.  
6.6.1.  Analgesic Use 
Analgesic use, both prescription an d OTC, will be collected in the eCRF in the same manner as 
other concomitant medications.  
6.7. Prohibited Therapies/Products  
Subjects enrolled in studies with pexidartinib who are also receiving concomitant warfarin 
should have their anti -coagulation status car efully monitored, especially shortly after initiation of 
pexidartinib, for the potential need for adjustments in warfarin dosing.  In particular, INR should 
be obtained just prior to initiation of pexidartinib, within 1 to 2 weeks after initiation, and 
periodically thereafter.  Dose adjustments of warfarin should be made as medically indicated.  
Although pexidartinib does not appear to inhibit CYP drug -metabolizing enzymes to an 
important extent, caution is warranted when administering pexidartinib to subjects taking drugs 
that are highly dependent on CYP for metabolism and have a narrow therapeutic index.  It is not 
known whether systemic exposure to these medications will increase while subjects are receiving 
pexidartinib.  
Of the 5 major CYP isoforms, 3A4 (BFC) may be involved in Phase 1 metabolism of 
pexidartinib, with possibly CYP1A2 playing a minor role. Concomitant use of strong CYP3A4 
inhibitors (Table  10.2) and inducers should be administered with caution, in the event they alter 
the systemic exposure to pexidartinib.  In general, strong inhibitors or inducers of CYP3A4 
should be avoided unless clinically necessary.  These inc lude anticonvulsants, certain mycin 
antimicrobials, and antiretrovirals.  
Restricted Therapies/Products  
If concomitant use with a strong CYP3A inhibitor (Table  10.2) or UGT inhibitor cannot be 
avoided , reduce the pexidartinib dose according to the recommendations in Table  6.5.  If 
concomitant use of a strong CYP3A inhibitor or UGT inhibitor is discontinued, increase the 
pexidartinib dose (after 3 plasma half -lives of the strong CYP3A inhibitor or UGT inhibitor) to 
the dose that was used before starting the  inhibitor.
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 43 Table  6.5: Recommended Dosage Reductions for Pexidartinib for Concomitant Use of 
Strong CYP3A Inhibitors or UGT Inhibitors  
Planned Total Daily Dose  Modified Total Daily Dose  Administration of  
Modified Total Daily Dose  
800 mg  400 mg  200 mg bid  
600 mg  400 mg  200 mg bid  
400 mg  200 mg  200 mg once daily  
bid = twice per day ; CYP = cytochrome P450; UGT = uridine 5' -diphospho -glucuronosyltransferase  
6.7.1.  Hormonal Contraceptives  
Pexidartinib has been indicated to be a moderate CYP3A4 inducer, as concurrent administration 
of pexidartinib decreased the AUCinf of the CYP3A4 substrate midazolam by 57%.  As the 
hormonal contraceptive ethinyl estradiol is a CYP3 A4 substrate, there is a potential that exposure 
of ethinyl estradiol may decrease on concurrent administration with pexidartinib.  As 
pexidartinib may cause embryo -fetal harm when administered to a pregnant woman, females of 
reproductive potential should be advised to use an effective, non -hormonal method of 
contraception during treatment with pexidartinib and for 1 month after the last dose.  Males with 
female partners of reproductive potential should be advised to use an effective method of 
contraception  during treatment with pexidartinib and for 1 month after the last dose.  Female 
partners of male patients should concurrently use effective contraceptive methods (hormonal or 
non-hormonal).  
6.7.2.  Acid -reducing Agents  
Avoid the concomitant use of proton pump inhibitors (PPI s) while taking pexidartinib.  As an 
alternative to a PPI, administer pexidartinib 2 hours before or 2 hours after taking a locally -
acting antacid, or if using a histamine 2 (H2) -receptor antagonist, administer pexidartinib at least 
2 hours before or 10 hours after taking an H2 -receptor antagonist . 
Permitted Therapies/Products  
Subjects are permitted to receive prophylactic or supportive treatment as standard of care during 
treatment , per Investigator ’s discretion and institutional guidelines.  
 Palliative radiation to non -measurable lesion is permitted as long as the radiation field 
does not include measurable lesion;  
 Investigator s’ discretion is recommended for the following:  
 Prophylactic or supportive treatment for expected toxicities, includi ng 
management of study drug will be as per  Investigator’s discretion.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 44 7. STUDY DRUG DISCONTINUATION AND DISCONTINUATION  
FROM THE STUDY  
This section describes  subjects who discontinue pexidartinib treatment as part of this study for 
reasons listed below and NOT  subjects who are participating in the Treatment -Free period  of the 
Treatment -Free/Re -Treatment Cohort . 
7.1. Subject Withdrawal/Discontinuation from the Study  
Subjects may discontinue from the study for any of the following reasons:  
 Completed  
 Complete Respon se 
 Death  
 Adverse Event  
 Progressive Disease  
 Clinical Progression  
 Lack of Efficacy  
 Withdrawal by Subject (to discontinue study drug)  
 Physician Decision  
 Lost to Follow -up (see Section  7.2 for details on when a subject is considered Lost to 
Follow -up) 
 Pregnancy  
 Protocol Deviation  
 Study Termination by Sponsor  
 Other  
If the reason for study discontinuation is the death of the subject, the options for categorizing the 
primary cause of death are progressive disease or adverse event.  If reason of death is unknown , 
every effort should be made to obtain the primary cause of death.  Only 1 AE will be recognized 
as the primary cause of death.  
Only subjects who refuse all of the following methods of follow -up will be considered to have 
withdrawn consent from study participation ( i.e., from the interventional portion and follow -up): 
 Attendance at study visits per protocol  
 Study personne l contacting the subject by telephone  
 Study personnel contacting an alternative person  
 Study personnel accessing and reviewing the subject’s medical information from 
alternative sources  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 45 If the subject refuses all of the above methods of follow -up, the Investigator  should personally 
speak to the subject to ensure the subject understands all of the potential methods of follow -up.  
If the subject continues to refuse all potential methods of follow up, the Investigator  will 
document this as a withdrawal of cons ent (from the interventional portion and follow -up). 
Withdrawal Procedures  
If a subject is withdrawn from the study:  
 The Investigator  will complete and report the observations as thoroughly as possible 
up to the date of withdrawal including the date of last dose, date of last contact, and 
the reason for withdrawal ; 
 If disclosure of future information is also withdrawn, the Sponsor may r etain and 
continue to use any data collected before such a withdrawal of consent ; 
 The subject  may request destruction of any samples taken and not tested, and the 
Investigator  must document this in the site study records ; 
 Study site personnel may use local , regional, and national public records (in 
accordance with local law) to monitor vital status.  
See Schedule of Events (Section  1.3) for data to be co llected at the time of study discontinuation 
and for any further evaluations that need to be completed.  
7.2. Lost to Follow -up 
A subject  will be considered lost to follow -up if he/she fails to return for scheduled visits and is 
unable to be contacted by the stu dy site staff.  Before a subject is deemed lost to follow -up, the 
Investigator  or designee will make every effort to regain contact with the subject (where 
possible, multiple  telephone calls, texts, emails, and if necessary, a certified letter to the subje ct’s 
last known mailing address or local equivalent methods).  These contact attempts should be 
documented.  
If direct contact with the subject is not possible , site personnel  must make every effort to collect 
survival status from public records ( e.g., obituaries, death certificates, etc.) in accordance with 
local laws.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 46 8. STUDY PROCEDURES  
See Schedule of Events (Section  1.3) for Screening, Baseline, Treatment, and EOS/ EOT  Follow -
up study procedures.  
8.1. Eligibility Assessment  
Review the subject's demographics, medical and target disease history  (if permitted via the 
subjects signed ICF, these may be transferred  from their prior study records) , vital signs, and 
results of tests  (e.g., physical exam ination , ECG , laboratory assessments) and compare against 
the eligibility criteria (Section  5.1 and Section  5.2). 
Informed Consent  
Before a subject’s participation in the study, it i s the Investigator ’s responsibility to obtain freely 
given consent in writing from the subject after adequate explanation of the aims, methods, 
anticipated benefits, and potential hazards of the study and before any protocol -specific 
procedures or any stud y drugs are administered.  Subjects should be given the opportunity to ask 
questions and receive responses to their inquiries and should have adequate time to decide 
whether or not to participate in the study.  The written ICF should be prepared in the loc al 
language(s) of the potential subject population.  See Section  10.1.2  for additional details.  
Tenosynovial Giant Cell Tumor History  
Subject’s TGCT  history will be obtained by the Investigator  or a qualified designee.   This may 
be obtained from the subject’s file from the prior  study.  
General Medical History and Baseline Conditions  
Subject’s medical history will be obtained by the Investigator  or a qualified designee.  
This may be obtained from the subject’s file from  the prior  study  (e.g., the concomitant 
medications taken during the course of the preceding study will be recorded under prior 
medications in PL3397 -A-U4003) .  Untoward medical occ urrence s (including clinically relevant 
laboratory values that are not symptoms of TGCT /vital signs that are out of range) that were 
diagnosed or known to exist prior to the consent date will be recorded on the General Medical 
History and Baseline Conditio ns eCRF, not the Adverse Event eCRF.  Record the start date of 
any medical occurrence that started before the ICF was signed and is ongoing at the time of the 
first dose of pexidartinib  on the General Medical History and Baseline Conditions eCRF.  
Demograph ics 
Review the subject’s demographics ; which , if permitted via the subjects signed ICF, may be 
transferred  from the subject’s file from the ir prior  study,  against the eligibility criteria.  
8.2. Enrollment  
Once a subject has been deemed eligible as per Section  5.1 and Section  5.2, the subject should be 
enrolled into this study.  For subjects choosing to continue treatment with pexidartinib, they will 
remain on their dosage level at the end of the prior study.  For subj ects choosing to enroll into the 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 47 Treatment -Free period of the Treatment -Free/Re-Treatment Cohort , pexidartinib treatment 
should be immediately stopped.  
8.3. Efficacy Assessments  
8.3.1.  Response Assessment  
Assess the subject based upon the local laboratory results usin g the Response Criteria 
(Section  10.4).  Additional details will be available in the Study Laboratory Manual.  
8.3.2.  Patient Reported Outcomes  
The PROMIS PF (Section  10.6.1 ) and EQ -ED-5L (Section  10.6.3 ) questionnaires will be used 
for PROs . 
8.3.3.  Radiographic Tumor Assessments  
The Investigator  will evaluate the MRI scans in order to perform a qualitative tumor assessment 
(i.e., stable disease).  These data will be used to inform the Investigator  and patient regarding the 
next steps in the course of treatment.  
The Sponsor may retain the MRI scans to retrospectively evaluate the tumor response , by central 
radiographic readers , for study and non -study related purposes . 
Individual subject outcomes by TVS will be classified according to the following criteria 
inspired by RECIST:  
 Complete response:  Lesion completely gone.  
 Partial response:  ≥50% decrease in volume score relative to baseline.  
 Progressive disease:  ≥30% increase in volume relative to lowest score during the 
study whether at baseline or some other visit.  
 Stable disease:  Does  not meet any of the prior criteria based on score during study.  
The cutoffs of 50% for partial response (PR) and ≥30% for progressive disease (PD) were 
developed in consultation with clinical experts.  
The TVS is a semi -quantitative MRI scoring system that describes tumor mass and is an 
extension of the 4-point synovitis scale of the well -established and widely used multi -feature 
score Rheumatoid Arthritis Magnetic Resonance Imaging ( RAMRIS ), originally deve loped for 
rheumatoid arthritis,8 and Whole -Organ Magnetic Resonance Imaging Score ( WORMS ), 
originally developed for osteoarthritis .9  The extended scale, the TVS, will be based on 10% 
increments of the estimated volume of the maximally distended synovial cavity or tendon sheath 
involved.  Thus, a tumor that is equal in volume to that of a maximally distended synovial cavity 
or tendon sheath will be scored 10, whereas a tumor that is 70% of that volume will be scored 7, 
a tumor that is twice the volume of the maximally distended syn ovial cavity or tendon sheath 
will be scored 20, and so on.  A score of “0” means no evidence of tumor.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 48 Re-Treatment Assessment  
At each visit, subjects who are in the Treatment -Free period  will be assessed by the Investigator 
for pexidartinib re -treatment based on Investigator and subject’s discretion . 
8.4. Safety Assessments  
8.4.1.  Adverse Event  
Method s to Detect Adverse Events  
The definitions of an AE , TEAE,  and SAE can be found in Section  9.5.2  and Section  10.5.  
Adverse events may be directly observed, reported spontaneously by t he subject or by 
questioning the subject (or, when appropriate, by a caregiver, surrogate, or the subject's legally 
authorized representative) at each study visit.  Subjects should be questioned in a general way, 
without asking about the occurrence of any specific symptoms.  Between scheduled clinic visits, 
subjects should be instructed to enter all AEs in their Diary.  The Investigator  must assess all 
AEs to determine seriousness, severity, and causality.  The Investigator  and any qualified 
designees are r esponsible for detecting, documenting, and recording events that meet the 
definition of an AE or SAE and remain responsible for following AEs that are serious, 
considered related to the study drug or study procedures, or that caused the subject to disconti nue 
pexidartinib . 
All clinical laboratory results, vital signs, and ECG results or findings should be appraised by the 
Investigator  to determine their clinical significance.  Isolated abnormal laboratory results, vital 
sign findings, or ECG findings ( i.e., not part of a reported diagnosis) should be reported as AEs 
if they are symptomatic, lead to study drug discontinuation, lead to dose reduction, require 
corrective treatment, or constitute an AE in the Investigator ’s clinical judgment.  
COVID -19 assessment s are detailed in  Section  8.4.4 . 
Time Period for Collecting Adverse Events, Serious Adverse Events  
All serious adverse events (SAEs) occurring after t he subject signs the ICF and up to 30 days 
after the last dose of study medication  if applicable  or EOS/FU visit , whether observed by the 
Investigator  or reported by the subject, will be recorded on the AE eCRF.  All SAEs will be 
followed until resolution,  stabilization, the event is otherwise explained, or the subject is lost to 
follow -up. 
All non -serious AEs occurring after the subject has taken the first dose of study medication/signs 
the ICF until 30 days after the last dose of study medication will be recorded on the AE  eCRF.  
Exacerbation of a pre -existing medical condition and symptom a fter the subject signs the ICF 
including increase in severity of the symptom will be recorded as an AE on the AE eCRF, unless 
it is a condition of TGCT . 
Reporting Procedure for Investigator s 
All AEs (including adverse events of special interest [ AESIs ] and SAEs) will be reported in the 
AE eCRF.  All AEs (serious and non -serious) must be reported with the Investigator ’s 
assessment of seriousness, severity, and causality to pexidartinib . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 49 Always report the diagnosis as the AE or SAE term.  When a diagnosis is unavailable, report the 
primary sign or symptom as the AE or SAE term with additional details included in the narrative 
until the diagnosis becomes available.  If the signs and symptoms are distinct and do not suggest 
a common diagnosis, report them as ind ividual entries of AE or SAE.  
Disease -Specific AEs and SAEs  
Disease progression/worsening of  TGCT will not be recorded as an AE on the Adverse Event 
eCRF.  However, events associated with disease progression, may be recorded as AEs.  
Death due to disease pr ogression should be recorded on the Death eCRF.  
8.4.1.1.  Serious Adverse Events Reporting  
The following types of events should be reported by the Investigator  in the  electronic data 
capture  (EDC ) or on a SAVER (Serious Adverse Event Report) form within 24 hours of 
awareness:  
 SAEs  (Section  10.5.2 ) 
 Hepatic events (both serious and non -serious) meeting the laboratory criteria of a 
potential Hy’s Law criteria (as defined in Section  8.4.1.2 ) 
 Overdose (as defined in Section  8.4.1.1.1 ) 
Details summarizing the course of the SAE, including its evaluation, treatment, and outcome 
should be provided.  Specific or estimated dates of AE onset, treatment, and resolution should be 
included.  Medical history, concomitant medications, and laboratory data that are relevant to the 
event should also be summarized in the SAE report.  For fatal events, the SAE report should 
state whether an autopsy was or will be performed and should includ e the results if available.  
Source documents (including medical reports) will be retained at the study site and should not be 
submitted to the Sponsor for SAE reporting purposes.  
If using EDC for SAE reporting: Complete the eCRF within 24  hours of awarene ss.  In the event 
that the eCRF is unavailable, report SAEs by faxing or emailing the SAVER Form  to Sponsor  or 
CRO  using the provided fax transmittal form and the appropriate fax number provided for the 
country or email address.  Once EDC becomes available, please enter SAEs reported on the 
SAVER Form into the eCRF as soon as possible.  Please refer to the eCRF Completion Guide  for 
additional instructions.  
Call the local SAE Hotline (see PL3397 -A-U4003 Study Site Manual ) or study monitor for any 
questions on SAE reporting.  
See Section  8.4.1  for details on the time period for collecting SAEs.  
Reporti ng Requirement to Sites and Regulatory Authorities  
The Sponsor/CRO  will inform Investigator s and regulatory authorities of any suspected 
unexpected serious adverse reactions (SUSARs) occurring in study sites or other studies of 
pexidartinib , as appropriate  per institutional and/or local reporting requirements.  
The Sponsor and/or CRO will inform Investigator s and regulatory authorities of all SAEs, 
regardless of relatedness, reported from this study, and any Suspected Unexpected Serious 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 50 Adverse Event Reactio ns (SUSARs) occurring in other studies of pexidartinib , as appropriate per 
institutional/local  reporting requirements.  
Sponsor or CRO  will comply with any additional local safety reporting requirements.  The 
Investigator  will assess if an AE is to be consi dered “unexpected” based on the “Reference 
Safety Information” section in the current pexidartinib IB.6 
Follow -up for AEs and SAEs  
The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated to elucidate the nature an d/or causality 
of the AE or SAE as fully as possible.  This may include additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care 
professionals.  
Urgent safety queries must be followed up and addre ssed promptly.  The Investigator  will submit 
any updated SAE data to the Sponsor or CRO  within 24 hours of receipt of the information.  
Follow -up information and response to non -urgent safety queries should be combined for 
reporting to provide the most com plete data possible within each follow -up report.  
8.4.1.1.1.  Overdose  
An overdose is defined as the accidental or intentional administration of any dose of a product 
that is considered both excessive and medically important.  All occurrences of overdose must be 
repor ted to Sponsor and/or CRO  within 24 hours of awareness.  Overdose will be reported via 
the SAVER/overdose  Form or eCRF.  
An “excessive and medically important” overdose includes any overdose in which either an 
SAE, a non -serious AE, or no AE occurs and is c onsidered by the Investigator  as clinically 
relevant, ie., poses an actual or potential risk to the subject.  
Occupational exposures must be reported via the SAVER form.  
8.4.1.2.  Adverse Events of Special Interest  
Pexidartinib can cause serious and potentially fatal  liver injury.  Hepatotoxicity with ductopenia 
and cholestasis occurred in patients treated with pexidartinib .  Across 768 patients who received 
pexidartinib  in clinical trials, there were 2 irreversible cases of cholestatic liver injury.  One 
patient died with advanced cancer and ongoing liver toxicity and 1 patient required a liver 
transplant.   The mechanism of cholestatic hepatotoxicity is unknown and its occurrence cannot 
be predicted.  
It is unknown whether liver injury occurs in the abs ence of increased transaminases.   Avoid 
pexidartinib in patients with pre -existing increased serum transaminases; total bilirubin or direct 
bilirubin (>ULN); or active liver or biliary tract disease, including increased ALP.  Taking 
pexidartinib with food increases drug exposure by 100% and may increase the risk of 
hepatotoxicity.  Administer pexidartinib on an empty stomach, at least 1 hour before or 2 hours 
after a meal or snack.  Monitor liver tests, including AST, ALT, total bilirubin, direct bilirubin,  
ALP and GGT, prior to initiation of pexidartinib, and as defined within the appropriate SoE for 
the cohorts  (Section  1.3).  Withhold and dose reduce,  or permanently discontinue pexidartinib 
based on the severity of the hepatotoxicity  (Table  6.3). 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 51 Combined Elevations of Aminotransferases and Bilirubin  
Hepatic events (both serious and non -serious) which meet the potential Hy’s Law criteria defined 
as an elevated (ALT and/or AST) ≥3 × ULN and an elevated TB IL >2 × ULN, regardless if it is 
due to disease progression per Investigator  assessment, that may oc cur at different time points 
during the study conduct, should always be reported to the Sponsor.  These events must be 
reported either by a SAVER form or eCRF, with the Investigator ’s assessment of seriousness, 
severity, causality, and a detailed narrative .  These events should be reported within 24 hours of 
Investigator ’s awareness of the event regardless of seriousness.  A targeted questionnaire will be 
available as an eCRF to collect relevant additional information for these potential cases.  
If the subje ct discontinues study drug due to liver enzyme abnormalities, the subject will have 
additional clinical and laboratory evaluations as described in Section  10.2 in order to determine 
the nature and severity of the potential liver injury.  
Additional information  can be found in the  PL3397 -A-U4003 Study Manual  and the Pexidartinib 
IB. 
8.4.2.  Pregnancy /Embryo -Fetal Toxicity  
Based on animal studies and its mechanism  of action, pexidartinib may cause fetal harm when 
administered to a pregnant woman.  Oral administration of pexidartinib to pregnant rats and 
rabbits during the period of organogenesis resulted in malformations, increased post -
implantation loss, and abort ion at exposures approximately equal to the human exposure at the 
recommended dose of 800 mg based on area under the curve (AUC).  
Advise pregnant women of the potential risk to a fetus.  As pexidartinib is a moderate CYP3A4 
inhibitor, concurrent administra tion of pexidartinib with ethinyl estradiol may lead to reduced 
exposure of ethinyl estradiol.   Females of reproductive potential should be advised to use an 
effective, non -hormonal method of contraception during treatment with pexidartinib and for 
1 month  after the last dose.  Males with female partners of reproductive potential should be 
advised to use an effective method of contraception during treatment with pexidartinib and for 1 
month after the last dose.  Female partners of male patients should concu rrently use effective 
contraceptive methods (hormonal or non -hormonal).  
Sponsor must be notified of any female subject or partner of a male subject who becomes 
pregnant while receiving or within  30 days of discontinuing pexidartinib . 
Although pregnancy is not technically an AE, all pregnancies must be followed to conclusion to 
determine their outcome.  If a pregnancy is reported, the Investigator  should inform the Sponsor 
within 24 hours of learning of the pregnancy.  
This information is important for both d rug safety and public health concerns.  It is the 
responsibility of the Investigator , or designee, to report any pregnancy in a female subject or 
partner of a male subject using the Exposure In Utero (EIU) Reporting Form .  Please contact 
your study monitor  to receive the EIU Reporting Form  upon learning of a pregnancy.  The 
Investigator  should make every effort to follow the female subject or partner of a male subject 
(upon obtaining written consent from partner) until completion of the pregnancy and comple te 
the EIU Reporting Form  with complete pregnancy outcome information, including normal 
delivery and induced abortion.  Any adverse pregnancy outcome, either serious or non -serious, 
should be reported in accordance with study procedures.  If the outcome of  the pregnancy meets 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 52 the criteria for immediate classification as a n SAE ( i.e., post-partum complications, spontaneous 
or induced abortion, stillbirth, neonatal death, or congenital anomaly, including that in an aborted 
fetus), the Investigator  should foll ow the procedures for reporting SAEs.  
Pregnancy Test  
For females of reproductive  potential (as defined in Section  5.1), document the results of a 
negative serum pregnancy test.   A positive pregnancy test at Screening will exclude female 
subject enrollment.  Any females enrolled in the study and receiving pexi dartinib who become 
pregnant must discontinue pexidartinib and communicate this information to the Investigator, 
and have the ir pregnancy followed to outcome.  
8.4.3.  Clinical Laboratory Evaluations  
The clinical laboratory tests including hematology, coagulation, serum  chemistry, TSH and 
urinalysis will be performed. De -identified laboratory reports with all local laboratory results 
from samples collected for hematology, coagulation, serum chemistry, TSH , and urinalysis will 
be collected on the local laboratory for m in EDC  to be data entered into the clinical database .  
Refer to Table  10.1 for the complete list of laboratory parameters.   Laboratories parameters  from 
the previous pexidartinib studies may be used at Baseline.  
Abnormal laboratory values (NCI -CTCAE Grade 3 or 4) occ urring during the clinical study will 
be followed until repeat test results return to normal (or Baseline ), stabilize, or are no longer 
clinically relevant , as determined by the Investigator .  New or worsened clinically relevant 
abnormalities should be rec orded as AEs on the Adverse Event eCRF.  
8.4.4.  Reporting of Exposure to COVID -19 (SARS -CoV -2) 
All confirmed or suspected COVID -19 events must be recorded in the eCRF.  
 Subjects who test positive for COVID -19 should be reported as “Confirmed COVID -19” 
either as an AE or serious adverse event (SAE).  
The usual protocol mandated SAE reporting requirements should be followed for confirmed or 
suspected COVID -19 (or SARS -CoV -2) as done for any other AE, ie, the Investigator should 
assess whether any seriousness criteria a re met per protocol, and appropriate protocol reporting 
requirements should be followed.  
In the event that the Investigator assesses that a COVID -19 case does not meet any seriousness 
criteria as outlined in the protocol, it should be reported as a non -serious AE in the eCRF.  
All study drug interruption or dose reduction or discontinuation due to the COVID -19 event must 
be recorded on the AE and drug administration eCRFs.  
For both serious and non -serious COVID -related AEs, the following information should b e 
provided as applicable:  
 Date and laboratory results confirming the COVID -19 diagnosis (including viral antigen 
test and/or antiviral antibody serological test) in the eCRF.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 53  Clinical course of the case, including presenting signs, symptoms, exposure, actions 
taken with the investigational products, medications used for treatment or prophylaxis of 
COVID -19, and outcome in relevant eCRF (eg, concomitant medication, AE).  
 Findings from diagnostic imaging (including computed tomography scan or other chest 
imaging).  
8.4.5.  Other Safety  
Physical Examinations  
A complete physical examination should include a weight measurement and an evaluation of the 
head, eyes, ears, nose, and throat and the cardiovascular, dermatological, musculoskeletal, 
respiratory, gastrointestin al, genitourinary, and neurological systems.  Any abnormality 
identified at Baseline should be recorded on the General Medical History and Baseline 
Conditions eCRF.  At subsequent visits (or as clinically indicated), limited, symptom -directed 
physical exam inations should be performed.  Changes from Baseline abnormalities should be 
collected in the subject’s study record.  New or worsened clinically relevant abnormalities should 
be recorded as AEs on the Adverse Event eCRF.  
Vital Signs  
Vital signs will inclu de the measurements of respiratory rate, heart rate, systolic and diastolic 
blood pressures, temperature, height ( may be obtained from subject’s prior  study file ), and body 
weight  [for Screening /Baseline this may be obtained from the subject’s prior  study] .  Vital signs 
should be taken prior to ECG measurement.  Blood pressure and pulse rate will be measured 
after the subject has rested in a recumbent position for at least 5  minutes and prior to laboratory 
draws.  
Electrocardiograms  
12 lead-electrocardiograms (ECGs) will be performed and recorded for every subject  at 
Screening .  The ECG will be measured after the subject has rested in a recumbent position for at 
least 5  minutes  and the ECG results will be read locally .  At any visit  during which a subject 
exhibits a heart rate ≤50 bpm or other clinical indications for ECG, the ECG will be repeated.  
Any abnormal finding should be confirmed with a repeated ECG.  Abnormal, clinically relevant 
findings occurring post -baseline will be re ported as AEs.  Whether or not the measurement is 
performed, the date the ECG is to be performed, heart rate, PR interval, RR interval, QRS 
amplitude, QT interval, QTcF interval, and results will be recorded in the eCRF.  
8.5. Pharmacokinetic (PK) Assessment (s) 
Not applicable . 
8.6. Pharmacodynamic Assessment (s) 
Not applicable . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 54 9. STATISTICAL  CONSIDERATIONS   
9.1. General Statistical Considerations  
This is a phase 4, multicenter study to evaluate the discontinuation and re -treatment of 
pexidartinib  in subjects with TGCT (PVNS o r GCT TS) who were previously treated with 
pexidartinib in one of the following studies: (PLX108 -10 (ENLIVEN), PLX108 -01, PL3397 -A-
A103, and PL3397 -A U126).  There is no statistical hypothesis for this study.  The statistical 
analysis will be descriptive i n nature.  No p -values will be reported.  
9.2. Statistical Hypothesis  
Not applicable.  
9.3. Sample Size Determination  
The study sample size is not based on statistical consideration.  Subjects currently enrolled in 
Studies PLX108 -10 (ENLIVEN), PLX108 -01, PL3397 -A-A103, and PL3397 -A-U126 who are 
eligible can participate in this study.  
9.4. Population for Analysis Sets  
Analysis Sets  
 The Safety Analysis Set will include all subjects who entered this study .  Subjects 
will be analyzed according to the ir cohort  (Trea tment -Free/Re -Treatment Cohort ; 
Treatment Continuation Cohort ). 
 The Full Analysis Set (FAS) for the Treatment -Free/Re -Treatment Cohort  will 
include all subjects who entered the Treatment -Free/Re -Treatment Cohort .  This data 
set will be the primary populati on for the primary endpoint.  
 The Full Analysis Set (FAS) for the Treatment Continuation Cohort  will include 
all subjects who entered the Treatment Continuation Cohort . 
 The Evaluable Analysis Set (EAS) will include all subjects who entered the study 
with Baseline measure and at least 1 post-baseline measures  available.  The data set 
will be used for PRO measures.  
 The Re -Treatment Analysis Set (RAS) will include all subjects who received at least 
1 dose of pexidartinib in the Treatment -Free/Re -Treatment Cohort after stopping 
pexidartinib.   The data will be used for both efficacy and safety analyses for 
re-treated subjects in the Treatment -Free/Re -Treatment Cohort . 
9.5. Statistical Analysis  
The Statistical Analysis Plan (SAP) will be developed and finalized before  database lock and 
will describe the subject populations to be included in the analyses, and procedures for 
accounting for missing, unused, and spurious data.  This section is a summary of the planned 
statistical analyses of the primary and secondary endpo ints. 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 55 9.5.1.  Efficacy Analyses  
Table  3.1 and Table  3.2 list the primary and secondary endpoints and their corresponding 
definitions of all endpoints.  Additional details for the analysis and censoring rules are noted in 
the following sections.  De tailed censoring rules for the primary and applicable secondary 
efficacy endpoints will be specified in the SAP.  
9.5.1.1.  Primary Efficacy Analyses  
The primary endpoint in this study is the proportion of subjects who remain treatment -free at 
Month 12 and Month 24 after entering the Treatment -Free period in the Treatment -Free/Re -
Treatment Cohort .  The primary efficacy analysis will be based on the data from the FAS.  
Kaplan -Meier methods will be used to estimate the proportion of subjects who remain 
treatment -free at Month 12  and Month 24 .  Estimate of the proportion will be provided with its 
95% confidence interval  (CI) using Greenwood’s formula . 
The subjects who resume pexidartinib treatment or died will be considered as an event.  The 
subjects who take subsequent systemic therapy or undergo surgery for the treatment of  TGCT 
will also be counted as an event.   The subjects who withdraw consent or lost to follow up with be 
censored at the last contact date . 
9.5.1.2.  Secondary Efficacy Analyses  
The PRO measures  will be summarized descriptively over time along with its 95% CI by each 
cohort.  The mean change from Baseline for these measures will also be reported over time along 
with its 95% CI by each cohort.  The analysis will be conducted in the  Evaluable Analysis Set 
(EAS).  
Similar analys es will be conducted in the Re-treatment  Analysis Set subjects (RAS).   In this 
analysis, the Baseline measure of the retreated subjects is defined as the latest measure prior to or 
on the date of re-treatment  of pexidartinib.  
Qualitative assessments of the tumor will be summarized  descriptively for pexidartinib re -treated 
subjects in the Treatment -Free/Re -Treatment Cohort  and for all subjects in the  Treatment 
Continuation Cohort . 
9.5.1.3.  Exploratory Analyses  
Exploratory analysis will be descriptive only.  Details of the exploratory analysis will be 
specified in the SAP.  
9.5.1.4.  Multiplicity Adjustment  
Not applicable . 
9.5.2.  Safety Analyses  
Safety analyses will be performed using the Safety Analysis Set and subjects will be a nalyzed by 
cohort separately . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 56 Adverse Events  
TEAEs  are defined as new AEs or pre -existing conditions that worsen in CTCAE grade after the 
first dose of study drug and up to 30 days after last dose of study drug.  AEs collected after 30 
days after the last dose of study drug will not be considered TEAEs unless they are treatment 
related .  AEs will be coded using the Medical Dictionary for Regulatory Activities  (MedDRA ) 
dictionary.  An AE will be assigned to the study period in which it started, even if it re solved in a 
subsequent period.  Incidence of TEAEs occurring over time, ( e.g., 0 to 6 months, 6 to 
12 months, etc.) will be summarized.  The number and percentage of subjects reporting TEAEs 
will be calculated overall, by system organ class, by preferred t erm, and by cohort . 
TEAEs  will be further summarized by CTCAE grade and relationship to study drug.  Similarly, 
the number and percentage of subjects reporting treatment -emergent SAEs and related treatment -
emergent SAEs will be tabulated, and TEAEs leading to discontinuation of st udy drug.  
A by -subject AE (including treatment -emergent) data listing including but not limited to 
verbatim term, preferred term, system organ class, CTCAE grade, and relationship to study drug 
will be provided.  Deaths, other SAEs, AESIs, and AEs associat ed with study drug 
discontinuation, will be listed.   AEs due to COVID -19 will be also summarized and listed.  
Clinical Laboratory Evaluation  
Descriptive statistics will be provided for the clinical laboratory results by scheduled time of 
evaluation and by cohort , as well as for the change from Baseline .  The Baseline value is defined 
as the last non -missing value before the initial administration of study drug.  In addition, mean 
change from Baseline will be presented for the maximum and minimum post -treatme nt values 
and the values at the EOT visit.  
Abnormal clinical laboratory results will be graded according to NCI-CTCAE  version  5.0, if 
applicable, and the grade will be presented in a by -subject data listing.  A shift table, presenting 
by cohort  the two -way frequency tabulation for baseline and the worst post -treatment value 
according to the CTCAE grade, will be provided for clinical laboratory tests.  A listing of 
abnormal clinical laboratory test results deemed of clinical significance or of Grade 3 or 4 w ill be 
generated.  
ECG  
Descriptive statistics will be provided for the ECG measurements by scheduled time of 
evaluation and by cohort, as well as for the change from Baseline.  The Baseline value is defined 
as the last non -missing value before the initial a dministration of study treatment.  A listing of 
ECG data will be generated.  
Vital Signs  
Descriptive statistics will be provided for the vital sign measurements by scheduled time of 
evaluation and by cohort , as well as for the change from Baseline .  The Baseline value is defined 
as the last non -missing value before the initial administration of study treatment.  A listing of 
vital sign data will be generated.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 57 Other  
Listings of all other safety endpoints ( e.g., physical examination findings) will be genera ted. 
9.5.3.  Other Analyses  
No other analyses are planned in this study.  
9.6. Interim Analyses  
Not applicable . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 58 10. APPENDICES – SUPPORTING DOCUMENTATION AND 
OPERATIONAL CONSIDERATIONS  
10.1. Appendix 1 :  Regulatory and Ethical Considerations  
10.1.1.  Regulatory Compliance  
The study protocol, the Investigator  Brochure, available safety information, recruitment 
procedures ( e.g., advertisements), subject information and consent form, any subject written 
instructions to be given to the subject, information about payments and co mpensation available 
to the subjects, and documentation evidencing the Investigator ’s qualifications should be 
submitted to the independent IRB or IEC for ethical review and approval according to local 
regulations, prior to the study start.  The written ap proval should identify all documents reviewed 
by name and version.  
Changes in the conduct of the study or planned analysis will be documented in a protocol 
amendment and/or the SAP.  Written approval of all protocol amendments and changes to any of 
the abo ve listed documents must be obtained from the IRB , IEC, and/or applicable regulatory 
authorities . 
The Investigator  should notify the IRB or IEC of deviations from the protocol or SAEs occurring 
at the study site and other AE reports received from the Spons or/CRO, in accordance with local 
procedures.  
The Sponsor will appoint a Coordinating Investigator .  Among other possible duties, the 
Coordinating Investigator  will be responsible for reviewing the Final Clinical Study Report and 
testifying to the accuracy of the description of the study conduct.  Because the Coordinating 
Investigator  should have personal knowledge of the conduct of the study, he or she will normally 
be chosen from among those Investigator s who have enrolled and treated at least 1 subject.  
However, where an Investigator  has special knowledge of the field or of the study, the 
Coordinating Investigator  can be chosen prior to enrollment of the first subject.  In all cases, the 
Coordinating Investigator  must be chosen prior to locking the databa se. 
Compliance Statement, Ethics, and Regulatory Compliance  
This study will be conducted in compliance with the protocol, the ethical principles that have 
their origin in the Declaration of Helsinki, the International Council for Harmonization (ICH) 
consol idated Guideline E6 for Good Clinical Practice (GCP) (CPMP/ICH/135/95), and 
applicable regulatory requirement(s) including the following:  
 European Commission Directive (2001/20/EC Apr 2001) and/or;  
 European Commission Directive (2005/28/EC Apr 2005) and/or ; 
 US Food and Drug Administration (FDA) GCP Regulations: Code of Federal 
Regulations (CFR) Title 21, parts 11, 50, 54, 56 and 312 as appropriate and/or;  
 Japanese Ministry of Health, Labor and Welfare Ordinance No. 28 (27  Mar 1997) 
and/or;  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 59  The Act on Securi ng Quality, Efficacy and Safety of Pharmaceuticals, Medical 
Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and 
Cosmetics No. 1 (25 Nov 2014);  
 Other applicable local regulations.  
In addition, the Investigator  will inform the Spo nsor in writing within 24 hours of any urgent 
safety measures taken by the Investigator  to protect the study subjects against any immediate 
hazard (s), and of any suspected/actual serious GCP non -compliance brought to the attention of  
the Investigator . 
Supply of New Information Affecting the Conduct of the Study  
When new information becomes available that may adversely affect the safety of subjects or the 
conduct of the study, the Sponsor will inform all Investigator s involved in the clinical study, 
ECs/ IRBs, and regulatory authorities of such information, and when needed, will amend the 
protocol and/or subject information.  
The Investigator  should immediately inform the subject whenever new information becomes 
available that may be relevant to the subject ’s consent or may influence the subject’s willingness 
to continue participation in the study.  The communication should be documented on medical 
records, for example, and it should be confirmed whether the subject is willing to remain in the 
study.  
If the subject information is revised, it must be re -approved by the EC/IRB.  The Investigator  
should obtain written informed consent to continue participation with the revised written 
information even if subjects were already informed of the relevant info rmation.  The Investigator  
or other responsible personnel who provided explanations and the subject should sign and date 
the revised ICF.  
10.1.2.  Informed Consent  
In obtaining and documenting informed consent, the Investigator  should comply with the 
applicable reg ulatory requirements, and should adhere to GCP and to the ethical principles that 
have their origin in the Declaration of Helsinki.  The ICF and any revision(s) should be approved 
by the EC/IRB prior to being provided to potential subjects.  
The subject’s w ritten informed consent should be documented in the subject’s medical records.  
The ICF  should be signed and personally dated by the subject and by the person who conducted 
the informed consent discussion (not necessarily the Investigator ).  The original s igned ICF 
should be retained in accordance with institutional policy, and a copy of the signed ICF should 
be provided to the subject.  The date and time (if applicable) that informed consent was given 
must be recorded in the eCRF.  
If the subject cannot rea d, then according to ICH GCP Guideline, Section 4.8.9, an impartial 
witness should be present during the entire informed consent discussion.  This witness should 
sign the ICF after the subject has consented to their participation.  By signing the ICF, the 
witness attests that the information in the ICF and any other written information was adequately 
explained to and apparently understood by the subject and that informed consent was freely 
given by the subject.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 60 A separate special consent for inherited genet ic analysis will be obtained from subjects in 
accordance with health authorities in their particular region/country.  
Suggested model text for the ICF for the study and any applicable subparts is provided in the 
Sponsor’s ICF template for the Investigator  to prepare the documents to be used at his or her 
study site.  Updates to applicable forms will be communicated via letter from the Sponsor.  
For study sites in the US, an additional consent is required for the Health Insurance Portability 
and Accountability  Act (HIPAA).  
10.1.3.  Subject Confidentiality  
The Investigator s and the Sponsor will preserve the confidentiality of all subjects taking part in 
the study, in accordance with GCP and local regulations.  
The Sponsor will observe the rules laid down in the European D ata Protection Directive 
95/46/EC and General Data Protection Regulation 2016/679 on the protection of individuals with 
regard to the processing of personal data and the free movement of such data.  
The Investigator  must ensure that the subject’s anonymity is maintained.  On the eCRFs or other 
documents submitted to the Sponsor or the CRO, subjects should be identified by a unique SID 
as designated by the Sponsor.  Documents that are not for submission to the Sponsor  or the CRO 
(e.g., signed ICF) should be kept in strict confidence by the Investigator . 
In compliance with ICH GCP Guidelines, it is required that the Investigator  and institution 
permit authorized representatives of the company, of the regulatory agency(s ), and the 
independent IRB/EC direct access to review the subject’s original medical records for 
verification of study -related procedures and data.  The Investigator  is obligated to inform the 
subject that his/her study -related records will be reviewed by the above -named  representatives 
without violating the confidentiality of the subject.  
10.1.4.  Data Integrity and Quality Assurance  
Monitoring and Inspections  
The CRO monitor and regulatory authority inspectors are responsible for contacting and visiting 
the Invest igator  for the purpose of inspecting the facilities and, upon request, inspecting the 
various records of the study ( e.g., eCRFs, source data, and other pertinent documents).  
The verification of adherence to the protocol; completeness, accuracy, and consist ency of the 
data; and adherence to ICH GCP and local regulations on the conduct of clinical research will be 
accomplished through a combination of onsite visits by the monitor and review of study data 
remotely.  The frequency of the monitoring visit will v ary based on the activity at each study 
site.  The monitor is responsible for inspecting the eCRFs and ensuring completeness of the 
study essential documents.  The monitor should have access to subject medical records and other 
study -related records needed  to verify the entries on the eCRFs.  Detailed information is 
provided in the PL3397 -A-U4003 Study Monitoring  Plan . 
The Monitor will communicate deviations from the protocol, SOPs, GCP and applicable 
regulations to the Investigator  and will ensure that app ropriate action (s) designed to prevent 
recurrence of the detected deviations is taken and documented.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 61 The Investigator  agrees to cooperate with the Monitor to ensure that any problems detected in the 
course of these monitoring visits are addressed to the satisfaction of the Sponsor and 
documented.  
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected for audit 
by representatives from the Sponsor.  Audit of study site facilities ( e.g., pharmacy, drug storage 
areas, laboratorie s) and review of study related records will occur in order to evaluate the study 
conduct and compliance with the protocol, ICH GCP, and applicable regulatory requirements.  
The Investigator  should respond to audit findings.  
In the event that a regulatory a uthority informs the Investigator  that it intends to conduct an 
inspection, the Sponsor shall be notified immediately.  
Data Collection  
An eCRF must be completed for each subject who signs an ICF and undergoes any screening 
procedure.  If a subject is not t reated, the reason must be recorded on the eCRF.  All data 
collected during the study will be recorded in this individual, subject -specific eCRF.  Instructions 
will be provided for the completion of the eCRF and any corrections made will be automatically 
documented via an “audit trail.”  
The eCRF should be kept current to enable the study monitor to review the subject’s status 
throughout the course of the study.  Upon completion of the subject’s eCRF, it will be reviewed 
and signed off by the Investigator  via the EDC system’s electronic signature.  This signature will 
indicate that the Investigator  inspected or reviewed the data in the subject -specific eCRF, the 
data queries, and the site notifications and agrees with the eCRF content.  
Data Management  
Each su bject will be identified in the database by a unique SID.  
To ensure the quality of clinical data across all subjects and study sites, a Sponsor  or CRO  
Clinical and Data Management review will be performed on subject data according to 
specifications developed by the Sponsor.  Data will be vetted both electronically by programmed 
data rules within the application and manually.  Queries generated by rules and raised by 
reviewers will be generated within the EDC application.  During this review, subject data will be 
checked for consistency, completeness and any apparent discrepancies.  
Data received from external sources such as local laboratories will be entered into the clinical 
database.  
All AEs will be coded using MedDRA.  Serious adverse events in the  clinical database will be 
reconciled with the safety database.  
All concomitant medications and prior cancer therapies will be coded using the World Health 
Organization Drug Reference (WHODRUG) Dictionary.  
10.1.5.  Committees  
Not applicable . 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 62 10.1.6.  Study Documentation and  Storage  
The Investigator  will maintain a Signature List of appropriately qualified persons to whom 
he/she has delegated study duties.  All persons authorized to obtain informed consent and make 
entries and/or corrections on eCRFs will be included on the S ignature List.  
Investigator s will maintain a confidential screening log of all potential study candidates that 
includes limited information of the subjects, date and outcome of the screening process.  
Investigator s will be expected to maintain an Enrollment  Log of all subjects enrolled in the study 
indicating their assigned study number.  
Investigator s will maintain a confidential subject identification code list.  This confidential list of 
names of all subjects allocated to study numbers on enrolling in the study allows the  Investigator  
to reveal the identity of any subject when necessary.  
Source documents are original documents, data, and records from which the subject’s eCRF data 
are obtained.  These include but are not limited to hospital records, clinical  and office charts, 
laboratory and pharmacy records, diaries, microfiches, X -rays, and correspondence.  
Electronic CRF entries may be considered source data if the eCRF is the site of the original 
recording ( i.e., there is no other written or electronic rec ord of data).  In this study, eCRF s may 
be used as source documents.  
Records of subjects, source documents, monitoring visit logs, data correction forms, eCRFs, 
inventory of study drug, regulatory documents ( e.g., protocol and amendments, IEC/IRB 
correspondence and approvals, approved and signed ICFs, Investigator ’s Agreement, clinical 
supplies receipts, distribution and return records), and other Sponsor correspondence pertaining 
to the study must be kept in appro priate study files at the study site (site specific Trial Master 
File).  Source documents include all recordings and observations or notations of clinical 
activities and all reports and records necessary for the evaluation and reconstruction of the 
clinica l study.  These records will be retained in a secure file for the period required by local 
laws or regulations or study site policy.  Prior to transfer or destruction of these records, the 
Sponsor must be notified in writing and be given the opportunity to  provide further instruction.  
Record Keeping  
The Investigator  and study site personnel are responsible for maintaining a comprehensive and 
centralized filing system (site specific Trial Master File) of all study -related (essential) 
documentation, suitable for inspection at any time by representatives from the Sponsor and/or 
applicable regulatory authorities.  Essential documents include:  
 Subject files containing completed eCRFs, ICFs, and supporting source 
documentation (if kept).  
 Study files containing the  protocol with all amendments, IB, copies of relevant 
essential documents required prior to commencing a clinical study, and all 
correspondence to and from the independent IRB/EC and the Sponsor.  
 Records related to the study drug(s) including acknowledgmen t of receipt at study 
site, accountability records and final reconciliation and applicable correspondence.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 63 In addition, all original source documents supporting entries in the eCRFs must be maintained 
and be readily available.  
All essential documentation w ill be retained by the Investigator  until at least 2 years* after the 
last approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region or at least 2 years* have lapsed since th e 
formal discontinuation of clinical development of the investigational drug.  These documents 
should be retained for a longer period, however, if required by the applicable laws or regulatory 
requirements or by an agreement with the Sponsor.  It is the re sponsibility of the Sponsor to 
inform the Investigator /Institution as to when these documents no longer need to be retained.  
Subjects’ medical files should be retained in accordance with applicable legislation and in 
accordance with the maximum period of t ime permitted by the hospital, institution or private 
practice.  
No study document should be destroyed without prior written agreement between the Sponsor 
and the Investigator .  Should the Investigator  wish to assign the study records to another party or 
move them to another location, he/she must notify the Sponsor in writing of the new responsible 
person and/or the new location.  
10.1.7.  Finances  
Prior to starting the study, the Principal Investigator  and/or Institution will sign a clinical study 
agreement with  the Sponsor.  This agreement will include the financial information agreed upon 
by the parties.  
Reimbursement, Indemnity, and Insurance  
The Sponsor provides insurance for study subjects to make available compensation in case of 
study -related injury.  
Reimburse ment, indemnity and insurance shall be addressed in a separate agreement on terms 
agreed upon by the parties.  
10.1.8.  Publication and Public Disclosure Policy  
The Sponsor is committed to meeting the highest standards of publication and public disclosure 
of information arising from clinical studies sponsored by the company.  The Sponsor will 
comply with participating country  policies for public disclosure of the clinical study protocol and 
clinical study results, and for sharing of clinical study data.  The Sponsor will follow the 
principles set forward in “Good Publication Practice for Communicating Company -Sponsored 
Medical Research (GPP3)”, and publications wil l adhere to the “Recommendations for the 
Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” 
established by the International Council of Medical Journal Editors (ICMJE).  
In order to ensure compliance with the public disclosu re policies and the ICMJE 
recommendations, and to protect proprietary information generated during the study, all 
publications (manuscripts, abstracts, or other public disclosure) based on data generated in this 
study must be reviewed and approved in writi ng by the Sponsor prior to submission.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 64 10.1.9.  Protocol Deviations  
The Investigator  should conduct the study in compliance with the protocol agreed to by the 
Sponsor and, if required, by the regulatory authority(ies), and which was given 
approval/favorable opinion  by the IECs/IRBs.  
A deviation to any protocol procedure or waiver to any stated criteria will not be allowed in this 
study except where necessary to eliminate immediate hazard(s) to the subject.  
The Sponsor must be notified in writing of all intended or u nintended deviations to the protocol 
(e.g., inclusion/exclusion criteria, dosing, missed study visits) within 24 hours of knowledge and 
in accordance with the clinical study agreement between the parties.  
The Investigator , or person designated by the Investigator , should document and explain any 
deviation from the approved protocol.  
If a subject was ineligible or received the incorrect dose or study treatment, and had at least 
1 administration of study drug, data should be collected for safety purposes . 
If applicable, the Investigator  should notify the IEC/IRB of deviations from the protocol in 
accordance with local procedures.  
10.1.10.  Study and Site Closure  
The Sponsor reserves the right to close the study site or terminate the study at any time for any 
reason  at the sole discretion of the Sponsor.  Study sites will be closed upon study completion.  A 
study site is considered closed when all required documents and study supplies have been 
collected and a study -site closure visit has been performed.  
The Investig ator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the Sponsor or Investigator  may include but are 
not limited to:  
 Failure of the Investigator  to comply with the protocol, the requirements of the 
IEC/IRB or local health authorities, the Sponsor's procedures, or GCP guidelines  
 Inadequate recruitment of subjects by the Investigator  
 Discontinuation of further  study intervention development  
Study termination may also be requested by (a) competent authority/ies.  
10.1.11.  Product Complaints  
A product complaint is any dissatisfaction with a product that may be attributed to the identity, 
quality, durability, reliability, o r safety of the product.  Individuals who identify a potential 
product complaint situation should immediately report the event.  Whenever possible, the 
associated product should be maintained in accordance with the label instructions pending 
further guidan ce from a quality representative form the Sponsor.  
For product complaints, refer to the PLX3397 -A-U4003 Pharmacy Manual  for instructions and 
details.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 65 10.2. Appendix 2 :  Laboratory  Assessments  
The clinical laboratory tests listed in Table  10.1 are to be performed in this study.  
Table  10.1: Clinical Laboratory Tests  
Test Analytes   
Blood Chemistry  albumin  
albumin globulin (A/G)  ratio (optional)  
alanine aminotransferase (ALT)  
alkaline phosphatase  (ALP)  
aspartate aminotransferase (AST)  
bilirubin  (total)  
bilirubin  (direct)  
blood urea nitrogen  (BUN)/urea  
calcium  (Ca) 
chloride  (Cl) 
creatinine  
cholesterol (total)  
creatin ine clearance (Cockcroft -Gault 
Equation)  creatine  phosphokinase  (CPK)  
gamma -glutamyl transaminase (GGT)  
glucose  (fasting)  
lactate  dehydrogenase  
lipase  
lipoprotein, high density /HDL -
cholesterol  
lipoprotein, low density /LDL-
cholesterol  
magnesium  (Mg)  
phosphorus  
potassium (K)  
protein  (total)  
sodium  (Na) 
triglycerides  
uric acid  
Hematology  hemoglobin  
hematocrit  
platelet count  
red blood cell (RBC)  count  
white blood cell (WBC)  count  differential WBC  count:  
basophils  
eosinophils  
lymphocytes  
monocytes  
neutrophils  
Coagulation  prothrombin time (PT) - international normalized ratio  (INR)  
activated partial thromboplastin time  (aPTT)  
optional:  partial thromboplastin time (PTT) if aPTT is not collected  
Urinalysis 
(abbreviated)  bilirubin  
glucose  
ketone  bodies  
occult  blood  
pH 
protein  urobilinogen  
sediments:  
casts  
RBC  
WBC  
Hormone testing  Follicular Stimulating Hormone (FSH) 
(females only)  
Thyroid Stimulating Hormone (TSH)  Baseline and B L-2 only 
 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 66 10.3. Appendix 3:  Reference Standards  
10.3.1.  Cockcroft -Gault Equation  
The estimated creatinine clearance (CrC L; mL/min) will be calculated using the Cockcroft -Gault 
equation based on [actual/ideal] weight in kilograms (1 kilogram = 2.2  pounds):10 
Conventional – serum creatinine in mg/dL:  
Male : 
CrCL (mL/min) =  
Female : 
CrCL (mL/min) =    × 0.85  
 
International System of Units (SI) – serum creatinine in μmol/L:  
Male : 
CrCL (mL/min) =  
Female : 
CrCL (mL/min) =           × 0.85  
10.3.2.  CYP3A4 Inhibitors and Inducers  
Table  10.2 lists the generic names of strong, moderate, and weak CYP3A4 inhibitor s.11  This is 
not a complete list and information for all non -listed medications should be confirmed against 
their prescribing information.  [140 - age (in years)] × weight (in kg)  
    serum creatinine (in mg/dL) × 72  
  [140 - age (in years)] × weight (in kg)  
      serum creatinine (in mg/dL) × 72  
   [140 - age (in years)] × weight (in kg)  
     serum creatinine ( in µmol/L ) × 72 × 0.0113  
      [140 - age (in years)] × weight (in kg)  
       serum creatinine (in µmol/L) × 72 × 0.0113  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 67 Table  10.2: CYP3A4 Inhibitors  
Inhibitor Type  Generic Drug Name  Allowance  
Strong  boceprevir  
clarithromycin  
conivaptan  
grapefruit  
grapefruit juice 
indinavir  
itraconazole  
ketoconazole  
lopinavir  
mibefradil  
nefazodone  
nelfinavir  
posaconazole  
ritonavir  
saquinavir  
telaprevir  
telithromycin  
voriconazole  Use should be avoided if 
possible.  
Requires pexidartinib dose 
reduction . 
Moderate  amprenavir  
aprepitant  
atazanavir  
ciprofloxacin  
crizotinib  
darunavir  
diltiazem  
erythromycin  
fluconazole  
fosamprenavir  
imatinib  
verapamil  Use allowed.   
No requirement for pexidartinib  
dose reduction.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 68 Inhibitor Type  Generic Drug Name  Allowance  
Weak  alprazolam  
amiodarone  
amlodipine  
atorvastatin  
bicalutamide  
cilostazol  
cimetidine  
cyclosporine  
fluoxetine  
fluvoxamine  
ginkgo  
goldenseal  
isoniazid  
lapatinib  
oral contraceptives  
nilotinib  
pazopanib  
ranitidine  
ranolazine  
ticagrelor  
tipranavir  
zileuton  Use allowed.  
No requirement for pexidartinib  
dose reduction  
Adapted from:  http://medicine.iupui.edu/clinpharm/ddis/main -table  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 69 10.4. Appendix 4:  Response Criteria  
The Investigator will evaluate the MRI scans to perform a qualitative tumor assessment (i.e., 
stable disease).  These data will be used to inform the Investigator and patient regarding the next 
steps in course of treatment.  
The Sponsor may retain the MRI scans for possible future (not study -related) use to 
retrospectively evaluate the tumor response (i.e., RECIST) and TVS by central radiographic 
readers, as outlined in the criteria below.  
Response Evaluation Criteria in Solid Tumors (Version 1.1)  
Assessment of tumor responses will be performed according to revised RECIST Guidelines , 
Version 1.1 .13  Some of these definitions  and criteria are highlighted below.  
Measurability of Tumor at Baseline Definitions  
At Baseline , tumor lesions/lymph nodes will be categorized as measurable or non -measurable as 
follows:  
Measurable  
Tumor lesions: Must be accurately measured in at least 1 dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:  
 10 mm by computed tomography ( CT) scan (CT scan slice thickness no greater than 5 
mm)  
 10 mm caliper measurement by clinical examination (lesions which cannot be 
accurately measured with calipers should be recorded as non -measurable)  
 20 mm by chest X -ray 
Measurable malignant lymph nodes: To be considered pathologically enlarged and measurable, a 
lymph node must be ≥15 mm in the short axis when assessed by CT sca n (CT scan slice 
thickness is recommended to be no greater than 5 mm).  At Baseline and quarterly scans , only 
the short axis will be measured and followed.  See also notes below on “Baseline documentation 
of target and non -target lesions” for information on lymph node measurement.  
Non-measurable  
All other lesions, including small lesions (longest diameter <10 mm or pathological lymph nodes 
with ≥10 to <15 mm short axis) as well as truly non -measurable lesions.  Lesions considered 
truly non -measurable inclu de leptomeningeal disease, ascites, pleural or pericardial effusion, 
inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal 
masses/abdominal organomegaly identified by physical examination that is not measurable by 
reproducible im aging techniques.  
Special Considerations Regarding Lesion Measurability  
Bone lesions, cystic lesions, and lesions previously treated with local therapy require particular 
comment:  
Bone lesions:  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 70  Bone scan, positron emission tomography (PET) scan or plain fi lms are not 
considered adequate imaging techniques to measure bone lesions.  However, these 
techniques can be used to confirm the presence or disappearance of bone lesions.  
 Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft tissue 
components, that can be evaluated by cross sectional imaging techniques such as CT 
or MRI can be considered as measurable lesions if the soft tissue component meets 
the definition of measurability described above.  
 Blastic bone lesions are non -measurable.  
Cystic lesions:  
 Lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non -measurable) since they 
are, by definition, simple cysts.  
 ‘Cystic lesions’ thought to represent c ystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above.  
However, if noncystic lesions are present in the same subject, these are preferred for 
selection as target lesions.  
Lesions with prior local treatment:  
 Tumor lesions situated in a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are not considered measurable unless there has been 
demonstrated progression in the lesion since the therapy.  
Specifications by  Methods of Measurements  
Measurement of Lesions  
All measurements should be recorded in metric notation, using calipers if clinically assessed.  
Method of Assessment  
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during quarterly scans .  Imaging -based evaluation 
should always be done rather than clinical examination unless the lesion(s) being followed 
cannot be imaged but are assessable by clinical examination.  
CT, MRI: CT is the best currently available and reproducible method to measure lesions selected 
for response assessment.  This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is 5 mm or less.  When CT scans have slice thickness 
greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  
MRI is also acceptable in certain situations ( e.g., for body scans).  
Tumor Response Evaluation  
Assessment of Overall Tumor Burden and Measurable Disease  
To assess objective response or future progression, it is necessary to estimate the overall tumor 
burden at Baseline and use this as a comparator for subsequent measurements.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 71 Baseline Documentation of ‘Target’ and ‘Non -Target’ Lesions  
When more than 1 measurable lesion is present at baseline all lesions up to a total of 2 lesions 
per organ and a maximum of 5 lesions total representative of all involved organs should be 
identified as target lesions and will be recorded and measured at baseline (this means in instances 
where subjects have only 1 or 2 organ sites involved a maximum of 2 and 4 lesions respectivel y 
will be recorded).  
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements.  It  may be the case that, on occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstance the next largest lesion which 
can be measured reproducibly should be selected.  
Lymph nodes merit special mention since they are no rmal anatomical structures which may be 
visible by imaging even if not involved by tumor.  As noted above, pathological nodes which are 
defined as measurable and may be identified as target lesions must meet the criterion of a short 
axis of ≥15 mm by CT sc an.  Only the short axis of these nodes will contribute to the baseline 
sum.  The short axis of the node is the diameter normally used by radiologists to judge if a node 
is involved by solid tumor.  Nodal size is normally reported as two dimensions in the plane in 
which the image is obtained (for CT scan this is almost always the axial plane; for MRI the plane 
of acquisition may be axial, sagittal, or coronal).  The smaller of these measures is the short axis.  
For example, an abdominal node which is report ed as being 20 mm × 30 mm has a short axis of 
20 mm and qualifies as a malignant, measurable node.  In this example, 20 mm should be 
recorded as the node measurement.  All other pathological nodes (those with short axis ≥10 mm 
but <15 mm) should be conside red non -target lesions.  Nodes that have a short axis <10 mm are 
considered non -pathological and should not be recorded or followed.  
A sum of the diameters (longest for non -nodal lesions, short axis for nodal lesions) for all target 
lesions will be calcula ted and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum.  The baseline 
sum diameters will be used as reference to further characterize any objective tumor  regression in 
the measurable dimension of the disease.  
All other lesions (or sites of disease) including pathological lymph nodes should be identified as 
non-target lesions and should also be recorded at baseline.  Measurements are not required,  and 
these  lesions should be followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal 
progression’.  
Evaluation of Target Lesions  
Complete Response (CR):  Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non -target) must have  reduction in short axis to <  10 mm.  
Partial Response (PR):  At least a 30% decrease in the sum of diameters of target lesions, taking 
as reference the baseline sum diameters.  
Progressive Disease (PD):  At least a 20% increase in the sum of diameters of targ et lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate an 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 72 absolute increase of at least 5 mm. ( Note:  the appea rance of 1 or more new lesions is also 
considered progression.)  
Stable Disease:  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify 
for PD, taking as reference the smallest sum diameters while on study.  
Special Notes on the As sessment of Target Lesions  
Lymph nodes:  Lymph nodes identified as target lesions should always have the actual short axis 
measurement recorded (measured in the same anatomical plane as the baseline examination), 
even if the nodes regress to below 10 mm on study.  This means that when lymph nodes are 
included as target lesions, the ‘sum’ of lesions may not be zero even if CR criteria are met, since 
a normal lymph node is defined as having a short axis of <  10 mm.  For PR, stable disease, and 
PD, the actual s hort axis measurement of the nodes is to be included in the sum of target lesions.  
Target lesions that become ‘too small to measure’:  All lesions (nodal and non -nodal) recorded 
at baseline should have their actual measurements recorded at each subsequent e valuation, even 
when very small ( e.g., 2 mm).  However, sometimes lesions or lymph nodes which are recorded 
as target lesions at baseline become so faint on CT scan that the radiologist may not feel 
comfortable assigning an exact measure and may report the m as being ‘too small to measure’.  
When this occurs, it is important that a value be recorded on the eCRF.  If it is the opinion of the 
radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm.  
If the lesion is belie ved to be present and is faintly seen but too small to measure, a default value 
of 5 mm should be assigned.  ( Note:  It is unlikely that this rule will be used for lymph nodes 
since they usually have a definable size when normal and are frequently surrounde d by fat such 
as in the retro -peritoneum.)  This default value is derived from the 5 mm CT slice thickness (but 
should not be changed with varying CT slice thickness.)  The measurement of these lesions is 
potentially non -reproducible; therefore,  providing this default value will prevent false responses 
or progressions based upon measurement error.  
If the Radiologist is able to provide an actual measurement, that should be recorded, even if it is 
below 5 mm.  
Lesions that split or coalesce on treatment:  When non -nodal lesions ‘fragment’, the longest 
diameters of the fragmented portions should be added together to calculate the target lesion sum.  
Similarly, as lesions coalesce, a plane between them may be maintained that would aid in 
obtaining maximal di ameter measurements of each individual lesion.  If the lesions have truly 
coalesced such that they are no longer separable, the vector of the longest diameter in this 
instance should be the maximal longest diameter for the ‘coalesced lesion’.  
Evaluation of  Non-Target Lesions  
Complete Response (CR):  Disappearance of all non -target lesions and normalization of tumor 
marker level.  All lymph nodes must be non -pathological in size (<10 mm short axis).  
Non-CR/Non -PD: Persistence of 1 or more non -target lesion(s)  and/or maintenance of tumor 
marker level above the normal limits.  
Progressive Disease (PD):  Unequivocal progression (see comments below) of existing non -
target lesions.  ( Note:  the appearance of 1 or more new lesions is also considered progression.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 73 Specia l Notes on Assessment of Progression of Non -target Disease  
The concept of progression of non -target disease requires additional explanation as follows, 
when the subject also has measurable disease.  In this setting, to achieve ‘unequivocal 
progression’ on the basis of the non -target disease, there must be an overall level of substantial 
worsening in non -target disease such that, even in presence of stable disease  (SD) or PR in target 
disease, the overall tumor burden has increased sufficiently to merit disc ontinuation of therapy.  
A modest ‘increase’ in the size of 1 or more non -target lesions is usually not sufficient to qualify 
for unequivocal progression status.  The designation of overall progression solely on the basis of 
change in non -target disease in  the face of SD or PR of target disease will therefore be extremely 
rare. 
New Lesions  
The appearance of new malignant lesions denotes disease progression; therefore, some 
comments on detection of new lesions are important.  There are no specific criteria f or the 
identification of new radiographic lesions; however, the finding of a new lesion should be 
unequivocal , i.e., not attributable to differences in scanning technique, change in imaging 
modality, or findings thought to represent something other than tu mor (for example, some ‘new’ 
bone lesions may be simply healing or flare of pre -existing lesions).  This is particularly 
important when the subject’s baseline lesions show partial or complete response.  For example, 
necrosis of a liver lesion may be report ed on a CT scan report as a ‘new’ cystic lesion, which it is 
not. 
A lesion in an anatomical location that was not scanned at baseline is considered a new lesion 
and will indicate disease progression.  An example of this is the subject who has visceral dise ase 
at baseline and while on study has a CT or MRI of the brain which reveals metastases.  The 
subject’s brain metastases are considered to be evidence of PD even if he/she did not have brain 
imaging at baseline.  
If a new lesion is equivocal, for example b ecause of its small size, continued therapy and follow -
up evaluation will clarify if it represents truly new disease.  If repeat scans confirm there is 
definitely a new lesion, then progression should be declared using the date of the initial scan that 
indicated its presence.  
Evaluation of Best Overall Response  
The best overall response is the best response recorded from the start of the study treatment until 
the EOT.  Confirmatory measurement for CR or PR is [not] required in this study.  The subject’s 
best overall response assignment will depend on the findings of both target and non -target 
disease and will also take into consideration the appearance of new lesions.  
Missing Assessments and In -evaluable Designation  
When no imaging/measurement is done at all at a particular time point, the subject is not 
evaluable (NE) at that time point.  If only a subset of lesion measurements is made at an 
assessment, usually the case is also considered NE at that time point, unless a convincing 
argument can be made tha t the contribution of the individual missing lesion(s) would not change 
the assigned time point response.  This would be most likely to happen in the case of PD.  For 
example, if a subject had a baseline sum of 50 mm with 3 measured lesions and at follow -up 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 74 only 2 lesions were assessed, but those gave a sum of 80 mm, the subject will have achieved PD 
status, regardless of the contribution of the missing lesion.  
Best Overall Response: All Time Points  
The best overall response is determined once all the data for the subject are known.  
Best response determination in studies where confirmation of complete or partial response IS 
NOT required: Best response in these studies is defined as the best response across all time 
points (for example, a subject who has stab le disease at first assessment, PR at second 
assessment, and PD on last assessment has a best overall response of PR).  When stable disease 
is believed to be best response, it must also meet the protocol specified minimum time from 
baseline (within 4 week s prior to the first dose of study drug), 7 weeks, in the case of scan 
intervals of 8 weeks (or “ 5 weeks”, in the case of scan intervals of 6 weeks .)  If the minimum 
time is not met when stable disease is otherwise the best time point response, the subject’ s best 
response depends on the subsequent assessments.  For example, a subject who has stable disease 
at first assessment, PD at second and does not meet minimum duration for stable disease, will 
have a best response of PD.  The same subject lost to follow -up after the first stable disease 
assessment would be considered NE.  
Table  10.3: Best Overall Response When Confirmation of CR and PR Required  
Overall response   Overall r esponse  
First time point  Subsequent time point  Best 
CR CR CR 
CR PR SD, PD or PR a 
CR SD SD provided minimum criteria for SD duration 
met, otherwise, PD  
CR PD SD provided minimum criteria for SD duration 
met, otherwise, PD  
CR NE SD provided minimum criteria for SD duration 
met, otherwise, PD  
PR CR PR 
PR PR PR 
PR SD SD 
PR PD SD provided minimum criteria for SD duration 
met, otherwise, PD  
PR NE SD provided minimum criteria for SD duration 
met, otherwise, PD  
NE NE NE 
CR = complete response; PR = partial response; SD = stable disease; NE = not evaluable; PD = progressive disease  
a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at  that point (since disease must have reappeared after CR).  
Best response would depend on whether minimum duration for SD was met.  However, sometimes ‘CR’ may be 
claimed when subsequent scans suggest small lesions were likely still present and in fact the  patient had PR, not 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 75 CR at the first time point.  Under these circumstances, the original CR should be changed to PR and the best 
response is PR.  
Source: Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revis ed 
RECIST guideline (version 1.1). Table 3. Euro J of Can. 2009:45;228 -47 
Special Notes on Response Assessment  
When nodal disease is included in the sum of target lesions and the nodes decrease to ‘normal’ 
size (< 10 mm), they may still have a measurement reported on scans.  This measurement should 
be recorded even though the nodes are normal in order not to overstate progression should it be 
based on increase in size of the nodes.  As noted earlier, this means that subjects with CR might 
not have a total s um of ‘0’ on the eCRF.  
Subjects with a global deterioration of health status requiring discontinuation of pexidartinib  
without objective evidence of disease progression at that time should be reported as ‘clinical 
progression.’  Every effort should be made  to document objective progression even after 
discontinuation of treatment.  Symptomatic deterioration is not a descriptor of an objective 
response: it is a reason for stopping study drug.  The objective response status of such subjects is 
to be determined  by evaluation of target and non -target disease.  If a radiographic tumor 
assessment has not been performed within 4 weeks of the time of clinical progression, then 
another radiographic assessment should be performed without waiting for the next regularly 
scheduled scan.  
For equivocal findings of progression ( e.g., very small and uncertain new lesions; cystic changes 
or necrosis in existing lesions), treatment may continue until the next scheduled assessment.  If at 
the next scheduled assessment, progression is confirmed, the date of progression should be the 
earlie r date when progression was suspected.  
Frequency of Tumor Re -evaluation  
In this study, tumor measurement will be conducted at Screening, and then at the intervals 
specified or sooner if clinically indicated.  The interval between scans is based on the last  scan 
visit.  Tumor measurement will be performed during the EOT visit if it was not done within the 
previous 8 weeks  or the previous assessment demonstrated disease progression.  
Baseline tumor assessments must be performed within 4 weeks prior to the firs t dose of study 
drug.  
All efforts should be made to ensure consistency between the Baseline measurements and all 
subsequent measurements in reference to utilization of scanning method, equipment, technique 
(including slice thickness and field of view), and  radiographic interpreter.  
The radiographic evaluation may include CT or MRI scanning of the chest, abdomen, and pelvis.  
Any additional suspected sites of disease should also be imaged.  All evaluations should meet the 
standard of care for imaging of lesions in the respective organ(s) and should conform to the 
image acquisition guidelines according to institutional standards.  
All target and non -target sites are evaluated at each time point of tumor assessment.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 76 10.5. Appendix 5:  General Information – Adverse  Events  
10.5.1.  Definition of Adverse Event  
An AE is any untoward medical occurrence in a subject administered a pharmaceutical product 
and that does not necessarily have to have a causal relationship with this treatment.  An AE can 
therefore be any unfavorable an d unintended sign (including an abnormal laboratory finding, for 
example), symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product .14 
It is the responsibility of Investigator s, based on their knowledge and experience, to determine 
those circumstances or abnormal laboratory findings which should be considered AEs.  
Events Meeting the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clin ically relevant in the 
medical and scientific judgment of the Investigator  (i.e., not related to progression of 
underlying disease).  
 Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity  of the condition.  
 New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, sympt oms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.  Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent.  Such overdoses should be reported regardless of sequelae.  
Events NOT Meeting the AE Definition  
 Any clinically relevant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
Inves tigator  to be more severe than expected for the subject’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition.  
 Medical  or surgical procedure ( e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 “Lack of efficacy” or “failur e of expected pharmacological action” per se will not be 
reported as an AE or SAE.  Such instances will be captured in the efficacy 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 77 assessments.  However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of efficacy will be reported as AE or SAE if they fulfill the definition of an AE 
or SAE.  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
10.5.2.  Serious Adverse Event  
A serious adverse event is a ny unt oward medical occurrence that at any dose:  
 Results in death  
 Is life -threatening  
 The term 'life -threatening' in the definition of 'serious' refers to an event in which 
the subject was at risk of death at the time of the event.  It does not refer to an 
event , which hypothetically might have caused death, if it were more severe  
 Requires inpatient hospitalization or prolongation of existing hospitalization  
 In general, hospitalization signifies that the subject has been detained (usually 
involving at least an ov ernight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting.  Complications that occur during 
hospitalization are AEs.  If a complication prolongs hos pitalization or fulfills any 
other serious criteria, the event is serious.  When in doubt as to whether 
“hospitalization” occurred or was necessary, the AE should be considered serious.  
 Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline or for administration of anticancer therapy after 
discontinuation of study drug is not considered an AE.  
 Results in persistent or significant disability/in capacity  
 The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomi ting, diarrhea, 
influenza, and accidental trauma ( e.g., sprained ankle) which may interfere with 
or prevent everyday life functions but do not constitute a substantial disruption.  
 Is a congenital anomaly/birth defect  
 Is an important medical event  
 Medical o r scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospitalization but may 
jeopardize the subjec t or may require medical or surgical intervention to prevent one 
of the other outcomes listed in the above definition.  These events should usually be 
considered serious.  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 78  Examples of such events include invasive or malignant cancers, intensive 
treatment in  an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.  
Events Exempted from SAE Reporting  
Serious events that are also efficacy endpoi nts and/or safety endpoints will be exempted from 
SAE processing and expedited reporting.14  Endpoints  are captured on designated eCRF.  These 
events are clinically anticipated events in the target treatment population . 
10.5.3.  Grade Assessment  
The severity of AEs will be graded using the latest NCI-CTCAE  (version 5.0).  For each episode, 
the highest severity grad e attained should be reported.  
The NCI-CTCAE  guidelines do not allow certain grades for certain AEs.  For example, pain can 
be Grade 1 to 3 only ( i.e., cannot be life -threatening or fatal), whereas sepsis can only be Grade 4 
or 5 ( i.e., can only be life -threatening or fatal).  In addition, alopecia can only be Grade 1 or 2.  
The NCI-CTCAE  guidelines should be followed closely.  
 Grade 1: Mild AE  
 Grade 2: Moderate AE  
 Grade 3: Severe AE  
 Grade 4: Life -threatening consequences; urgent intervention indicated  
 Grade  5: Death related to AE  
Difference between Severity and Seriousness  
The term "severe" is often used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial infarction); the event itself, however, may be of relat ively minor 
medical significance (such as severe headache).  This is not the same as "serious," which is based 
on subject/event outcome or action criteria usually associated with events that pose a threat to a 
subject's life or functioning.  Seriousness (n ot severity) serves as a guide for defining regulatory 
reporting obligations.  
10.5.4.  Causality Assessment  
The Investigator  should assess causal relationship between an adverse event and the study drug 
based on his/her clinical judgment and the following definitio ns.  The causality assessment must 
be made based on the available information and can be updated as new information becomes 
available.  
 Related:  
 The AE follows a reasonable temporal sequence from study drug administration 
and cannot be reasonably explained by the subject’s clinical state or other factors 
(e.g., disease under study, concurrent diseases, and concomitant medications).  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 79 or 
 The AE follows a reasonable temporal sequence from study drug administration 
and is a known reaction to the drug under study (or its chemical group) or is 
predicted by known pharmacology.  
 Not Related:  
 The AE does not follow a reasonable sequence from study drug administration or 
can be reasonably explained by the subject’s clinical state or other factors ( e.g., 
disease under stu dy, concurrent diseases, and concomitant medications).  
10.5.5.  Action Taken Regarding Study Drug (s) 
 Dose Not Changed: No change in study drug dosage was made.  
 Drug Withdrawn: The study drug was permanently stopped.  
 Dose Reduced: The dosage of study drug was reduce d. 
 Drug Interrupted: The study drug was temporarily stopped.  
 Not Applicable  
 Unknown: Subject is lost to follow -up 
10.5.6.  Other Action Taken for Event  
 None.  
 No treatment was required.  
 Medication required.  
 Prescription and/or over the counter medication was requir ed to treat the adverse 
event.  
 Hospitalization or prolongation of hospitalization required.  
 Hospitalization was required or prolonged due to the AE, whether or not 
medication was required.  
 Other.  
10.5.7.  Adverse Event Outcome  
 Recovered/Resolved  
 The subject fully r ecovered from the AE with no sequelae observed.  
 Recovered/Resolved with Sequelae  
 The subject fully recovered from the AE but with sequelae.  
 Recovering/Resolving  
 The AE is improving but not recovered  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 82 10.6.2.  PROMIS Item Bank v. 1.2 – Physical Functioning (Upper Extremity)  
Please respond to each item by marking 1 box per row.  
  Without 
any 
difficulty  With a 
little 
difficulty  With 
some 
difficulty  With 
much 
difficulty  Unable 
to do  
PFB34  Are you able to change a light bulb overhead?
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
       
PFA16r1  Are you able to dress yourself, including tying 
shoelaces and buttoning up your clothes? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
  Not at all  Very 
little Somewhat  Quite a 
lot Cannot 
do 
PFB54  Does your health now limit you in going OUTSIDE the 
home, for example to shop or visit a doctor’s office? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
       
PFA4  Does your health now limit you in doing heavy work 
around the house like scrubbing floors, or lifting or 
moving heavy furniture? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
  Without 
any 
difficulty  With a 
little 
difficulty  With 
some 
difficulty  With 
much 
difficulty  Unable 
to do 
PFA12  Are you able to push open a heavy door? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
       
PFB28r1  Are you able to lift 10 pounds (5 kg) above your 
shoulder?
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
       
PFA14r1  Are you able to carry a heavy object (over 10 pounds/5 
kg)? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
  Not at all  Very 
little Somewhat  Quite a 
lot Cannot 
do 
PFB1  Does your health now limit you in doing moderate work 
around the house like vacuuming, sweeping floors or 
carrying in groceries? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
       
PFA5  Does your health now limit you in lifting or carrying 
groceries? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 83   Without 
any 
difficulty  With a 
little 
difficulty  With 
some 
difficulty  With 
much 
difficulty  Unable 
to do 
PFA42  Are you able to carry a laundry basket up a flight of 
stairs? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
       
PFA13  Are you able to exercise for an hour? 
 ................................ ................................ .......................   □ 
5 □ 
4 □ 
3 □ 
2 □ 
1 
       
 
 
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 84 10.6.3.  EQ-5D-5L 
 
 
 
Health Questionnaire  
 
 
English version for the USA  
 
 
 
 
 
 
 
1 
USA (English) © 2009 EuroQol Group. EQ -5D™ is a trade mark of the EuroQol Group

Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 85 Under each heading, please check the ONE box that best describes your health TODAY  
 
MOBILITY  
I have no problems walking       ❑ 
I have slight problems walking     ❑ 
I have moderate problems walking      ❑ 
I have severe problems walking      ❑ 
I am unable to walk       ❑ 
 
SELF -CARE  
I have no problems washing or dressing myself   ❑ 
I have slight problems washing or dressing myself   ❑ 
I have moderate problems washing or dressing myself  ❑ 
I have severe problems washing or dressing myself  ❑ 
I am unable to wash or dress myself     ❑ 
 
USUAL ACTIVITIES  (eg work, study, housework,  
family or leisure activities)  
I have no problems doing my usual activities   ❑ 
I have slight problems doing my us ual activities   ❑ 
I have moderate problems doing my usual activities  ❑ 
I have severe problems doing my usual activities   ❑ 
I am unable to do my usual activities    ❑ 
 
PAIN / DISCOMFORT  
I have no pain or discomfort      ❑ 
I have slight pain or discomfort     ❑ 
I have moderate pain or discomfort     ❑ 
I have severe pain or discomfort     ❑ 
I have extreme pain or discomfort     ❑ 
 
ANXIETY / DEPRESSION  
I am not anxious or depressed     ❑ 
I am slightly anxious or depressed     ❑ 
I am moderately anxious or depressed    ❑ 
I am severely anxious or depressed     ❑ 
I am extremely anxious or depressed    ❑ 
 
 
 
 
 
 
 
 
 
2 
USA (English) © 2009 EuroQol Group. EQ -5D™ is a trade mark of the EuroQol Group  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 87 11. REFERENCES  
1. Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced 
tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 
Aug 10;  394(10197):478 -487. 
2. Coffelt SB, Hughes R, Lewis CE. Tumor -associated macrophages: effectors of 
angiogenesis and tumor progression. Biochem Biophys Acta. 2009;1796(1):11 –8. 
3. Tam WF, Gilliland DG. Can FLT3 inhibitors overcome resistance in AML? Best Pract 
Res Cl in Haematol. 2008;21:13 –20. 
4. Fletcher JA, Rubin BP. KIT mutations in GIST. Curr Opin Genet Dev. 2007;17:3 –7. 
5. O’Sullivan B, Cummings B, Catton C, et al. Outcome following radiation treatment for 
high-risk pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys. 1995;32:777 –
86. 
6. Pexidartinib Investigator’s Brochure, Edition 1 3.0. Daiichi Sankyo, Basking Ridge, NJ. 
03 Nov 2021 . 
7. Gerhardt JJ, Cocchiarella L, Lea RD. The Practical Guide to Range of Motion 
Assessment. Chicago, IL. Amer Med Assoc Press; 2002.  
8. Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT Rheumatoid Arthritis Magnetic 
Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, 
and the OMERACT RA -MRI scoring system. J Rheumatol. 2003;30(6):1385 –6. 
9. Peterfy C, Guerma zi A, Zaim S, et al. Whole -Organ Magnetic Resonance Imaging Score 
(WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage. 2004;12(3):177 –90. 
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. 
Nephron 1976;16:31 -41. 
11. Flockhart DA (2007). Drug Interactions: Cytochrome P450 Drug Interaction Table. 
http://medicine.iupui.edu/clinpharm/ddis/main -table. Indiana University School of 
Medicine  
12. Heads of Medicines Agencies. Clinical Trial Facilitation Group (CTFG). 
Recommendations  related to contraception and pregnancy testing in clinical trials. 
September 2014. http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 - 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf  
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New r esponse evaluation criteria in solid 
tumours: Revised RECIST guideline (version 1.1). Euro J Can. 2009:45;228 –47. 
14. ICH E2A Guideline. Clinical Safety Data Management: Definitions and Standards for 
Expedited Reporting, Oct 1994. 
https://www.ich.org/fileadmin /Public_Web_Site/ICH_Products/Guidelines/Effica 
cy/E2A/Step4/E2A_Guideline.pdf  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 88 12. LIST OF ABBREVIATIONS  
Abbreviation  Definition  
ADR  adverse drug reaction  
AE adverse event  
AESI  adverse event of special interest  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AML  acute  myeloid leukemia  
ASCO  American Society of Clinical Oncology  
AST  aspartate aminotransferase  
AUC  area under the curve  
BID twice a day  
CI confidence interval  
CFR  code of federal regulations  
CR complete response  
CrCl  creatinine clearance  
CRF  case report form  
CRO  contract research organization  
CSF1R  Colony stimulating factor 1 receptor  
CSF1  Colony stimulating factor 1  
CT computed tomography  
CTC  common toxicity criteria  
CTCAE  common terminology criteria for adverse events  
CYP  cytochrome P450  
DMC  data monitoring committee  
DSI Daiichi -Sankyo, Inc.  
EAS  evaluable  analysis set  
EC ethics committee  
ECI event of clinical interest  
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
EIU exposure in utero  
EOS  End of Study  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 89 Abbreviation  Definition  
EOT  End of Treatment  
EQ-5D-5L European Quality of Life Five Dimension Five Level Scale  
EU European Union  
FAS full analysis set  
FDA  Food and Drug Administration  
FMS  feline McDonough sarcoma  
FSH follicle stimulating hormone  
GCP  good clinical practice  
GCT -TS giant cell tumor of the tendon sheath [  
GGT  gamma -glutamyl transferase  
GI gastrointestinal  
GISTs  Gastrointestinal stromal tumors  
H2 histamine 2  
HIPAA  health insurance portability and accountability act  
IB Investigator ’s Brochure  
ICF informed consent form  
ICH International Conference on Harmonisation  
ICMJE  International Council of Medical Journal Editors  
IEC independent ethics committee  
INN interna tional non -proprietary name  
INR international normalized ratio  
IRB institutional review board  
LFT liver function test  
M-CSF macrophage -colony stimulating factor  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance imaging  
NCI National Cancer Institute  
NCI-CTCAE  National Cancer Institute – Common Terminology Criteria for Adverse Events  
NE not evaluable  
ORR  overall response rate  
OS overall survival  
OTC  over-the-counter  
PET positron emission tomography  
PD progressive disease  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 90 Abbreviation  Definition  
PFS progression -free survival  
PR partial response  
pRBC  packed red blood cell  
PPI proton pump inhibitors  
PROs  patient reported outcomes  
PROMIS  PF Patient -Reported Outcomes Measurement Information System – Physical 
Function  
PVNS  pigmented villonodular synovitis  
QTc corrected QT interval  
QTcF  QT interval corrected with Fridericia’s formula  
RAMRIS  Rheumatoid Arthritis Magnetic Resonance Imaging  
RAS  re-treatment a nalysis set  
RECIST  response evaluation criteria in solid tumors version 1.1  
RES response evaluable set  
SAE  serious adverse event  
SAP statistical analysis plan  
SAVER  Serious Adverse Event Report  
SCF stem cell growth factor  
SCR  Screening  
SD stable disease  
SID subject identifier  
SOC  system organ class  
SoE Schedule of Events  
SOP Standard Operating Procedure  
SUSAR  suspected unexpected serious adverse reaction  
TAMs  Tumor -associated macrophages  
TBIL  total bilirubin  
TEAE  treatment -emergent adverse event  
TGCT  Tenosynovial giant cell tumor  
TVS  tumor volume score  
UGT  Uridine 5' -diphospho -glucuronosyltransferase  
ULN  upper limit of normal  
US United States  
WHO  World Health Organization  
Protocol PL3397 -A-U4003  
Version 2.0, 25 Feb 2022  
Proprietary and Confidential  
Page 91 Abbreviation  Definition  
WHODD  World Health Organization Drug Dictionary  
WORMS  Whole -Organ Magnetic Resonance Imaging Score   
 
Signature Page for VV-CLIN-096041
PL3397-A-U4003:  A PHASE 4, MULTICENTER STUDY TO EVALUATE DISCONTINUATION AND RE
Signature Page for VV-CLIN-096041Approval with eSign
Medical Affairs
04-Mar-2022 12:32:00 GMT+0000
Approval with eSign
Medical Affairs
04-Mar-2022 14:48:27 GMT+0000
Approval with eSign
CSPV
07-Mar-2022 19:55:46 GMT+0000
Approval with eSign
BDM
10-Mar-2022 22:58:56 GMT+0000
PPD
PPD
PPD
PPD